<?xml version="1.0" standalone="no"?>
<!DOCTYPE ALGORITHM SYSTEM 
  "http://sierra2.stanford.edu/sierra/ASI2.dtd">

<ALGORITHM>
    <ALGNAME>HIVDB</ALGNAME>
    <ALGVERSION>6.3</ALGVERSION>

    <DEFINITIONS>
    	<GENE_DEFINITION>
    	   <NAME>PR</NAME>
    	   <DRUGCLASSLIST>PI</DRUGCLASSLIST>
    	</GENE_DEFINITION>

    	<GENE_DEFINITION>
    	   <NAME>RT</NAME>
    	   <DRUGCLASSLIST>NNRTI, NRTI</DRUGCLASSLIST>
    	</GENE_DEFINITION>

    	<GENE_DEFINITION>
    	   <NAME>IN</NAME>
    	   <DRUGCLASSLIST>INI</DRUGCLASSLIST>
    	</GENE_DEFINITION>

        <LEVEL_DEFINITION>
            <ORDER>1</ORDER>
            <ORIGINAL>Susceptible</ORIGINAL>
            <SIR>S</SIR>
        </LEVEL_DEFINITION>

        <LEVEL_DEFINITION>
            <ORDER>2</ORDER>
            <ORIGINAL>Potential low-level resistance</ORIGINAL>
            <SIR>S</SIR>
        </LEVEL_DEFINITION>

        <LEVEL_DEFINITION>
            <ORDER>3</ORDER>
            <ORIGINAL>Low-level resistance</ORIGINAL>
            <SIR>I</SIR>
        </LEVEL_DEFINITION>

        <LEVEL_DEFINITION>
            <ORDER>4</ORDER>
            <ORIGINAL>Intermediate resistance</ORIGINAL>
            <SIR>I</SIR>
        </LEVEL_DEFINITION>

        <LEVEL_DEFINITION>
            <ORDER>5</ORDER>
            <ORIGINAL>High-level resistance</ORIGINAL>
            <SIR>R</SIR>
        </LEVEL_DEFINITION>
  
        <DRUGCLASS>
            <NAME>PI</NAME>
            <DRUGLIST>FPV/r,IDV/r,LPV/r,NFV,SQV/r,ATV/r,TPV/r,DRV/r</DRUGLIST>
        </DRUGCLASS>

        <DRUGCLASS>
            <NAME>NRTI</NAME>
            <DRUGLIST>AZT,D4T,DDI,3TC,FTC,ABC,TDF</DRUGLIST>
        </DRUGCLASS>

        <DRUGCLASS>
            <NAME>NNRTI</NAME>
            <DRUGLIST>NVP,EFV,ETR,RPV</DRUGLIST>
        </DRUGCLASS>

        <DRUGCLASS>
            <NAME>INI</NAME>
            <DRUGLIST>RAL,EVG,DTG</DRUGLIST>
        </DRUGCLASS>

        <GLOBALRANGE>
            (-INF TO 9  => 1, 
             10 TO 14   => 2, 
             15 TO 29   => 3,
             30 TO 59   => 4,
             60 TO INF  => 5)
        </GLOBALRANGE>

	<COMMENT_DEFINITIONS>
	    <COMMENT_STRING id="PR_DRVr_Special">
		<TEXT>The following $numberOfMutsIn{11I,32I,33F,47V,50V,54LM,74P,76V,84V,89V} of the 11 darunavir/r POWER/DUET study mutations were present: $listMutsIn{11I,32I,33F,47V,50V,54LM,74P,76V,84V,89V} (DeMeyer S et al, EHDRW 2008).</TEXT>
		<SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

	    <COMMENT_STRING id="PR_TPVr_Special">
		<TEXT>This sequence has $numberOfMutsIn{47V,54AMV,58E,74P,82LT,83D} major TPV/r-resistance mutations ($listMutsIn{47V,54AMV,58E,74P,82LT,83D}), $numberOfMutsIn{10V,36I,43T,46L,84V} minor TPV/r-resistance mutations ($listMutsIn{10V,36I,43T,46L,84V}), and $numberOfMutsIn{24I,50LV,54L,76V} mutations associated with increased TPV/r responsiveness ($listMutsIn{24I,50LV,54L,76V}).  RESIST study (Baxter J et al J Virology 2006 and Scherer J et al EACS 2007).</TEXT>
		<SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

	    <COMMENT_STRING id="RT_ETR_Special">
                <TEXT>The following $numberOfMutsIn{90I,98G,100I,101EPH,106I,138A,179DFT,181CIV,190AS,230L} of the 17 etravirine DUET study mutations were present: $listMutsIn{90I,98G,100I,101EPH,106I,138A,179DFT,181CIV,190AS,230L} (Katlama C et al, IAS 2007).</TEXT>
		<SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

<!-- Begin the PR mutation-dependent comment strings. -->
            <COMMENT_STRING id="PR_POS10ACDEGHKMNPQSTWdi_Other">
                <TEXT>L10I/V/F/R/Y are PI-selected mutations. $listMutsIn{10ACDEGHKMNPQSTWdi} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS10IVFRY_PIMinor">
                <TEXT>L10I/V/F/R/Y are associated with resistance to most PIs when present with other mutations. L10I/V occur in 5-10% of untreated persons. L10F is a non-polymorphic mutation which is associated with decreased susceptibility to all PIs except ATV/r, SQV/r, and TPV/r. L10R/Y are rare poorly characterized mutations.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS11IL_PIMinor">
                <TEXT>V11IL are PI-selected mutation that are weakly associated with decreased FPV/r and DRV/r susceptibility.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS20ACDEFGHLNPQSWYdi_Other">
                <TEXT>K20R/M/I/T/V are associated with resistance to multiple PIs when present with other mutations. $listMutsIn{20ACDEFGHLNPQSWYdi} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS20RMITV_Other">
                <TEXT>K20R/M/I/T/V are PI-selected mutations. K20R is highly polymorphic and probably makes the least contribution to decreased PI susceptibility. K20I/M/T/V are nonpolymorphic in most subtypes. They appear to be selected most commonly by NFV and to reduce its susceptibility.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS23ACDEFGHKMNPQRSTVWYdi_Other">
                <TEXT>L23I is a rare substrate cleft mutation that causes low-level NFV resistance. $listMutsIn{23ACDEFGHKMNPQRSTVWYdi} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS23I_PIMinor">
                <TEXT>L23I is a rare substrate cleft mutation that causes low-level NFV resistance.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS24ACDEGHKMNPQRSTVWYdi_Other">
                <TEXT>L24I is associated with reduced susceptibility to IDV/r and LPV/r and possibly SQV/r, and ATV/r when present with other mutations. It increases TPV/r susceptibility. L24F is a rare mutation at this position; its phenotypic effect is not known. $listMutsIn{24ACDEGHKMNPQRSTVWYdi} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS24F_Other">
                <TEXT>L24I is associated with reduced susceptibility to IDV/r and LPV/r and possibly SQV/r, and ATV/r when present with other mutations. It increases TPV/r susceptibility. L24F is a rare mutation at this position; its phenotypic effect is not known.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS24I_PIMinor">
                <TEXT>L24I is associated with reduced susceptibility to IDV/r and LPV/r and possibly SQV/r, and ATV/r when present with other mutations. It increases TPV/r susceptibility.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS30ACEFGHIKLMPQRSTVWYdi_PIMinor">
                <TEXT>D30N causes high-level resistance to NFV. $listMutsIn{D30ACEFGHIKLMPQRSTVWYdi} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS30N_PIMajor">
                <TEXT>D30N causes high-level resistance to NFV.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS32ACDEFGHKLMNPQRSTWYdi_PIMinor">
                <TEXT>V32I is a substrate cleft mutation which is associated with reduced susceptibility to all PIs except SQV/r. $listMutsIn{V32ACDEFGHKLMNPQRSTWYdi} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS32I_PIMajor">
                <TEXT>V32I is a substrate cleft mutation which is associated with reduced susceptibility to all PIs except SQV/r.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS33F_PIMinor">
                <TEXT>L33F is selected by FPV/r, DRV/r, LPV/r, ATV/r, and TPV/r, and contribute resistance to these drugs.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS33I_PIMinor">
                <TEXT>L33F is selected by FPV/r, DRV/r, LPV/r, ATV/r, and TPV/r, and contribute resistance to these drugs. L33I is less common than L33F but may have a similar effect.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS33V_Other">
                <TEXT>L33V is a polymorphism that does not appear to be related to PI therapy or drug resistance.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS35G_PIMinor">
                <TEXT>E35G is a nonpolymorphic mutation that is selected by NFV and which is weakly associated with decreased TPV susceptibility.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS36ILTV_Other">
                <TEXT>M36I is weakly associated with PI resistance in subtype B viruses when present with other mutations. However, M36I is the consensus amino acid in most non-B subtypes. M36L/V/T are uncommon mutations at this position of unknown significance.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS43T_PIMinor">
                <TEXT>K43T is a nonpolymorphic PI-selected accessory mutation that in combination with other mutations is associated with reduced susceptibility to most PIs. It is also part of the genotypic susceptibility score (GSS) for TPV/r.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS46ACDEFGHKNPQRSTWYdi_PIMinor">
                <TEXT>M46I/L decreases susceptibility to IDV/r, NFV, FPV/r, LPV/r, and ATV/r when present with other mutations. M46V is an uncommon PI-selected mutation at this position. $listMutsIn{46ACDEFGHKNPQRSTWYdi} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS46IL_PIMajor">
                <TEXT>M46I/L decreases susceptibility to IDV/r, NFV, FPV/r, LPV/r, and ATV/r when present with other mutations.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS46V_PIMinor">
                <TEXT>M46I/L decreases susceptibility to IDV/r, NFV, FPV/r, LPV/r, and ATV/r when present with other mutations. M46V is an uncommon PI-selected mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS47A_PIMajor">
                <TEXT>I47A usually occurs with V32I and in this setting causes high-level LPV/r and FPV/r resistance and decreased DRV/r susceptibility.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS47CDEFGHKLMNPQRSTWYdi_PIMinor">
                <TEXT>I47V decrease susceptibility to FPV/r, ATV/r, IDV/r, LPV/r, TPV/r, and DRV/r. I47A usually occurs with V32I and in this setting causes high-level LPV/r and FPV/r resistance and decreased DRV/r susceptibility. $listMutsIn{47CDEFGHKLMNPQRSTWYdi} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS47V_PIMajor">
                <TEXT>I47V decrease susceptibility to FPV/r, ATV/r, IDV/r, LPV/r, TPV/r, and DRV/r.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS48ASTQL_PIMajor">
                <TEXT>G48V causes high-level SQV/r resistance, intermediate ATV/r and NFV resistance, and low-level IDV/r and LPV/r resistance.G48M is a less common mutation that appears to have similar effects on ARV susceptibility.  G48A/S/T/Q are rare PI-selected mutations.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS48CDEFHIKNPRWYdi_PIMinor">
                <TEXT>G48V causes high-level SQV/r resistance, intermediate ATV/r and NFV resistance, and low-level IDV/r and LPV/r resistance. G48M is a less common mutation that appears to have similar effects on ARV susceptibility.  G48A/S/T/Q/L are rare PI-selected mutations.  $listMutsIn{48(NOT VMALSTQL)} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS48M_PIMajor">
                <TEXT>G48V causes high-level SQV/r resistance, intermediate ATV/r and NFV resistance, and low-level IDV/r and LPV/r resistance. G48M is a less common mutation that appears to have similar effects on ARV susceptibility.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS48V_PIMajor">
                <TEXT>G48V causes high-level SQV/r resistance, intermediate ATV/r and NFV resistance, and low-level IDV/r and LPV/r resistance.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS50ACDEFGHKMNPQRSTWYdi_PIMinor">
                <TEXT>I50V causes intermediate-to-high-level resistance to FPV/r, low-intermediate resistance to LPV/r and DRV/r, and increased susceptibility to TPV/r. I50L causes intermediate-to-high level resistance to ATV/r and increased susceptibility to the remaining PIs. $listMutsIn{50ACDEFGHKMNPQRSTWYdi} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS50L_PIMajor">
                <TEXT>I50L causes intermediate-to-high level resistance to ATV/r and increased susceptibility to the remaining PIs.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS50V_PIMajor">
                <TEXT>I50V causes intermediate-to-high-level resistance to FPV/r, low-intermediate resistance to LPV/r and DRV/r, and increased susceptibility to TPV/r.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS53ACDEGHIKMNPQRSTVWdi_Other">
                <TEXT>F53L is associated with decreased susceptibility to SQV and ATV. F53Y is a rare PI-selected variant at this position. $listMutsIn{53ACDEGHIKMNPQRSTVWdi} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS53LY_PIMinor">
                <TEXT>F53L is associated with decreased susceptibility to SQV/r and ATV/r. F53Y is a rare PI-selected variant at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS54CDEFGHKNPQRWYdi_PIMinor">
                <TEXT>I54V/M/L/A/T/S have diverse effects on PI susceptibility. $listMutsIn{54CDEFGHKNPQRWYdi} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS54L_PIMajor">
                <TEXT>I54L occurs in patients receiving FPV/r, LPV/r, and DRV/r and reduces susceptibility to these PIs and to NFV and possibly ATV/r. It increases TPV/r susceptibility.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS54M_PIMajor">
                <TEXT>I54M is selected by FPV/r, LPV/r, and DRV/r and reduces susceptibility to each of the PIs.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS54TAS_PIMajor">
                <TEXT>I54T/A/S are PI-related mutations in combination with other mutations are associated with decreased susceptibility to each of the PIs. However, their effects have not been as well studied as I54V, I54M, or I54L.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS54V_PIMajor">
                <TEXT>I54V contributes resistance to each of the PIs except DRV/r. It is synergistic with V82A/S/T in decreasing PI susceptibility.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS58E_PIMinor">
                <TEXT>Q58E is a nonpolymorphic PI-selected mutation associated with decreased susceptibility to TPV/r and possibly other PIs.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS63P_Other">
                <TEXT>L63P is a common polymorphism that is also selected by PIs.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS71TVIL_PIMinor">
                <TEXT>A71T/V are polymorphisms that occur in 2-3% of untreated persons but which increase in frequency in persons receiving PIs. A71I/L are nonpolymorphic mutations that occur in viruses with multiple PI-resistance mutations.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS73STCA_PIMinor">
                <TEXT>G73S/T/C/A are selected by and appear to be associated with decreased susceptibility to most, if not all, PIs. Their effect on SQV/r and NFV and possibly ATV/r appears to be greater than their effect on other PIs.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS74P_PIMinor">
                <TEXT>T74P is a nonpolymorphic mutation that occurs more commonly in heavily treated patients. It has been associated with decreased virological response to TPV/r and to a lesser extent DRV/r. It is probably associated with decreased susceptibility to multiple PIs.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS74S_Other">
                <TEXT>T74S is associated with reduced NFV susceptibility. It occurs in about 5% of untreated persons with subtype C viruses.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS76ACDEFGHIKMNPQRSTWYdi_PIMinor">
                <TEXT>L76V reduces susceptibility to FPV/r, IDV/r, LPV/r, and DRV/r and increases susceptibility to SQV/r, ATV/r, and TPV/r. $listMutsIn{76ACDEFGHIKMNPQRSTWYdi} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS76V_PIMajor">
                <TEXT>L76V reduces susceptibility to FPV/r, IDV/r, LPV/r, and DRV/r and increases susceptibility to SQV/r, ATV/r, and TPV/r.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS77I_Other">
                <TEXT>V77I is a common polymorphism that is selected by NFV.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS82A_PIMajor">
                <TEXT>V82A reduces susceptibility to IDV/r and LPV/r. With other mutations it is associated with reduced susceptibility to NFV, ATV/r, SQV/r, and FPV/r.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS82C_PIMajor">
                <TEXT>V82C is a rare mutation that occurs primarily in protease genes containing multiple other PI-resistance mutations.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS82DEGHKNPQRWYdi_PIMinor">
                <TEXT>V82A/T/F/L/M/S/C have diverse effects on multiple PIs. $listMutsIn{82DEGHKNPQRWYdi} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS82F_PIMajor">
                <TEXT>V82F reduces susceptibility to IDV/r, LPV/r, FPV/r, DRV/r, and NFV.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS82I_Other">
                <TEXT>V82I is a polymorphism that is common in some non-B subtypes; it has little if any effect on PI susceptibility.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS82L_PIMajor">
                <TEXT>V82L is a rare TPV/r-selected mutation which decreases TPV/r susceptibility. Its effect on other PIs has not been characterized.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS82M_PIMajor">
                <TEXT>V82M reduces IDV/r, LPV/r susceptibility in subtype G viruses. Its effect on other PIs has not been studied.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS82S_PIMajor">
                <TEXT>V82S probably has a similar effect to V82T which reduces susceptibility to IDV/r, LPV/r, and TPV/r and with other mutations is associated with reduced susceptibility to NFV, ATV/r, FPV/r, and SQV/r.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS82T_PIMajor">
                <TEXT>V82T reduces susceptibility to IDV/r, LPV/r, and TPV/r. With other mutations it is associated with reduced susceptibility to NFV and ATV/r.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS83ACEFGHIKLMPQRSTVWYdi_Other">
                <TEXT>N83D is a nonpolymorphic mutation that occurs more commonly in heavily treated patients. It is associated with a decreased virological response to TPV/r and probably contributes decreased susceptibility to other PIs. $listMutsIn{83ACEFGHIKLMPQRSTVWYdi} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS83D_PIMinor">
                <TEXT>N83D is a nonpolymorphic mutation that occurs more commonly in heavily treated patients. It is associated with a decreased virological response to TPV/r and probably contributes decreased susceptibility to other PIs.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS84AC_PIMajor">
                <TEXT>I84V causes intermediate/high-level resistance to ATV/r, FPV/r, IDV/r, NFV, and SQV/r; and low-level resistance to LPV/r, TPV/r, and DRV/r. I84A is an uncommon mutation that causes at least similar levels of resistance to each of the PIs. I84C is an even less common mutation that has not been well-characterized.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS84DEFGHKLMNPQRSTWYdi_PIMinor">
                <TEXT>I84V causes intermediate/high-level resistance to ATV/r, FPV/r, IDV/r, NFV, and SQV/r; and low-level resistance to LPV/r, TPV/r, and DRV/r. I84A is an uncommon mutation that causes at least similar levels of resistance to each of the PIs. I84C is an even less common mutation that has not been well-characterized. $listMutsIn{84DEFGHKLMNPQRSTWYdi} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS84V_PIMajor">
                <TEXT>I84V causes intermediate/high-level resistance to ATV/r, FPV/r, IDV/r, NFV, and SQV/r; and low-level resistance to LPV/r, TPV/r, and DRV/r.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS85V_Other">
                <TEXT>I85V is a nonpolymorphic PI-selected mutation.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS88ACEFHIKLMPQRVWYdi_Other">
                <TEXT>N88S causes high-level resistance to NFV and ATV/r and low-level resistance to IDV/r; it increases susceptibility to FPV/r. N88T/G are rare PI-selected mutations that have much less pronounced effects than N88S. $listMutsIn{88ACEFHIKLMPQRVWYdi} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS88D_PIMinor">
                <TEXT>N88D is selected by NFV. In combination with D30N, it synergistically reduces NFV susceptibility.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS88S_PIMajor">
                <TEXT>N88S causes high-level resistance to NFV and ATV/r and low-level resistance to IDV/r; it increases susceptibility to FPV/r.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS88TG_PIMajor">
                <TEXT>N88S causes high-level resistance to NFV and ATV/r and low-level resistance to IDV/r; it increases susceptibility to FPV/r. N88T/G are rare PI-selected mutations that have much less pronounced effects than N88S.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS89IT_Other">
                <TEXT>L89T/I are non-polymorphic PI-selected mutation of uncertain phenotypic and clinical significance.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS89M_Other">
                <TEXT>L89M is a common polymorphism that is not associated with decreased PI susceptibility.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS89V_PIMinor">
                <TEXT>L89V is a nonpolymorphic PI-selected accessory mutation which emerges commonly during treatment with DRV/r and in combination with other mutations is associated with decreased virological response to DRV/r salvage therapy.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS90ACDEFGHIKNPQRSTVWYdi_PIMinor">
                <TEXT>L90M reduces susceptibility to NFV, SQV/r, ATV/r, and IDV/r. When present with other mutations it also reduces susceptibility to FPV/r and LPV/r. $listMutsIn{90ACDEFGHIKNPQRSTVWYdi} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS90M_PIMajor">
                <TEXT>L90M reduces susceptibility to NFV, SQV/r, ATV/r, and IDV/r. When present with other mutations it also reduces susceptibility to FPV/r and LPV/r.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS93L_Other">
                <TEXT>I93L is a common polymorphism. It is the consensus residue in most subtypes. In subtype B, it is weakly associated with PI treatment.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="PR_POS93M_Other">
                <TEXT>I93M is a rare PI-associated mutation; its effect on PI susceptibility is not known.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>
<!-- End the PR mutation-dependent comment strings. -->

<!-- Begin the RT mutation-dependent comment strings. -->
            <COMMENT_STRING id="RT_POS40F_NRTI">
                <TEXT>E40F is a nonpolymorphic mutation selected by AZT and d4T. It usually occurs in combination with M41L, L210W, and T215Y and in this context increases resistance to each of the NRTIs</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS41ACDEFGHKNPQRSTVWYdi_Other">
                <TEXT>$listMutsIn{41ACDEFGHKNPQRSTVWYdi} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS41I_Other">
                <TEXT>M41I is an artifact resulting from APOBEC3G-mediated hypermutation.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS41L_NRTI">
                <TEXT>M41L usually occurs with T215Y. M41L+T215Y confer high-level resistance to AZT and d4T and intermediate resistance to ddI, ABC, and TDF. However, in viruses with M184VI, resistance to AZT and d4T will be intermediate and resistance to TDF will be low-level.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS44AD_Other">
                <TEXT>E44AD are relatively nonpolymorphic accessory NRTI-resistance mutations that occur in combination with multiple TAMs.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS62CDEFGHIKLMNPQRSTWYdi_Other">
                <TEXT>A62V is a nonpolymorphic mutation commonly associated with K65R and with Q151M-associated multinucleoside resistance. It is also associated with T69 insertions. Its effect in the absence of these mutations is not known. $listMutsIn{62CDEFGHIKLMNPQRSTWYdi} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS62V_NRTI">
                <TEXT>A62V is a nonpolymorphic mutation commonly associated with K65R and with Q151M-associated multinucleoside resistance. It is also associated with T69 insertions. Its effect in the absence of these mutations is not known.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS65ACDEFGHILMPQSTVWYdi_NRTI">
                <TEXT>K65RN are known NRTI-resistance mutations. $listMutsIn{65ACDEFGHILMPQSTVWYdi} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS65N_NRTI">
                <TEXT>K65R causes intermediate/high-level phenotypic and clinical resistance to TDF, ddI, ABC, and d4T. It causes low/intermediate phenotypic and clinical resistance to 3TC and FTC. K65R increases AZT susceptibility both phenotypically and clinically. K65N is a rare mutation with similar but weaker effects than K65R on NRTI susceptibility.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS65R_NRTI">
                <TEXT>K65R causes intermediate/high-level phenotypic and clinical resistance to TDF, ddI, ABC, and d4T. It causes low/intermediate phenotypic and clinical resistance to 3TC and FTC. K65R increases AZT susceptibility both phenotypically and clinically.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS66d_NRTI">
                <TEXT>Amino acid deletions (d) between codons 66 to 71 are rare and usually occur in combination with either multiple TAMs, the Q151M mutation complex, or K65R. Deletions that are closer to position 67 are more often associated with multiple TAMs. Deletions that are closest to position 69 are more often associated with the Q151M complex or K65R.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS66i_NRTI">
                <TEXT>Double amino acid insertions (i) between codons 66 to 71 most often align to codon 69 and occur in less than 1% of heavily treated persons. Together with TAMs, they confer high-level resistance to AZT, d4T, ddI, ABC, and TDF, and intermediate/high-level resistance to 3TC and FTC.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS67ACFIKLMPQRVWYi_NRTI">
                <TEXT>D67N contributes low-level resistance to AZT and d4T. It decreases susceptibility to ABC, TDF, and ddI when present with multiple TAMs. D67GESTH are nonpolymorphic NRTI-selected mutations that generally occur in viruses with multiple TAMs. $listMutsIn{67ACFIKLMPQRVWYi} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS67EGSTQH_NRTI">
                <TEXT>D67N contributes low-level resistance to AZT and d4T. It decreases susceptibility to ABC, TDF, and ddI when present with multiple TAMs. D67GESTH are nonpolymorphic NRTI-selected mutations that generally occur in viruses with multiple TAMs.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS67N_NRTI">
                <TEXT>D67N contributes low-level resistance to AZT and d4T. It decreases susceptibility to ABC, TDF, and ddI when present with multiple TAMs.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS67d_NRTI">
                <TEXT>Amino acid deletions (d) between codons 66 to 71 are rare and usually occur in combination with either multiple TAMs, the Q151M mutation complex, or K65R. Deletions that are closer to position 67 are more often associated with multiple TAMs. Deletions that are closest to position 69 are more often associated with the Q151M complex or K65R.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS67i_NRTI">
                <TEXT>Double amino acid insertions (i) between codons 66 to 71 most often align to codon 69 and occur in less than 1% of heavily treated persons. Together with TAMs, they confer high-level resistance to AZT, d4T, ddI, ABC, and TDF, and intermediate/high-level resistance to 3TC and FTC.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS68d_NRTI">
                <TEXT>Amino acid deletions (d) between codons 66 to 71 are rare and usually occur in combination with either multiple TAMs, the Q151M mutation complex, or K65R. Deletions that are closer to position 67 are more often associated with multiple TAMs. Deletions that are closest to position 69 are more often associated with the Q151M complex or K65R.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS68i_NRTI">
                <TEXT>Double amino acid insertions (i) between codons 66 to 71 most often align to codon 69 and occur in less than 1% of heavily treated persons. Together with TAMs, they confer high-level resistance to AZT, d4T, ddI, ABC, and TDF, and intermediate/high-level resistance to 3TC and FTC.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS69CFHKLMPQRVWYd_NRTI">
                <TEXT>T69DNSGAIEi are NRTI-selected mutations. $listMutsIn{69CFHKLMPQRVWYd} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS69D_NRTI">
                <TEXT>T69D is associated with decreased susceptibility to ddI and d4T.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS69G_NRTI">
                <TEXT>T69G usually occurs in combination with multiple NRTI-resistance mutations often in combination with a deletion at codon 67. By itself it reduces susceptibility to ddI, d4T, ABC, and possibly TDF.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS69N_NRTI">
                <TEXT>T69N is a relatively nonpolymorphic mutation selected by AZT, d4T, and ddI-containing regimens. T69N may contribute low-level decreased susceptibility to AZT, d4T, and ddI.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS69SAIE_Other">
                <TEXT>T69SAIE are relatively non-polymorphic mutations that are weakly selected by NRTI exposure. Their effects on NRTI susceptibility, if any, are not well characterized.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS69d_NRTI">
                <TEXT>Amino acid deletions (d) between codons 66 to 71 are rare and usually occur in combination with either multiple TAMs, the Q151M mutation complex, or K65R. Deletions that are closer to position 67 are more often associated with multiple TAMs. Deletions that are closest to position 69 are more often associated with the Q151M complex or K65R.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS69i_NRTI">
                <TEXT>Double amino acid insertions (i) between codons 66 to 71 most often align to codon 69 and occur in less than 1% of heavily treated persons. Together with TAMs, they confer high-level resistance to AZT, d4T, ddI, ABC, and TDF, and intermediate/high-level resistance to 3TC and FTC.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS70ACDFHILMPVWYdi_NRTI">
                <TEXT>K70EG reduce TDF, ABC, DDI, and to a lesser extent 3TC and FTC susceptibility. K70QNST are rare non-polymorphic NRTI-selected mutations that appear to have similar but possibly weaker phenotypic effects than K70EG. $listMutsIn{70(NOT EGNQRSTR)} is an unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS70EG_NRTI">
                <TEXT>K70EG reduce TDF, ABC, DDI, and to a lesser extent 3TC and FTC susceptibility. K70E increases AZT susceptibility.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS70QNST_NRTI">
                <TEXT>K70EG reduce TDF, ABC, DDI, and to a lesser extent 3TC and FTC susceptibility. K70QNST are rare non-polymorphic NRTI-selected mutations that appear to have similar but possibly weaker phenotypic effects than K70EG.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS70R_NRTI">
                <TEXT>K70R causes intermediate resistance to AZT and low-level resistance to d4T and TDF.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS70d_NRTI">
                <TEXT>Amino acid deletions (d) between codons 66 to 71 are rare and usually occur in combination with either multiple TAMs, the Q151M mutation complex, or K65R. Deletions that are closer to position 67 are more often associated with multiple TAMs. Deletions that are closest to position 69 are more often associated with the Q151M complex or K65R.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS70i_NRTI">
                <TEXT>Double amino acid insertions (i) between codons 66 to 71 most often align to codon 69 and occur in less than 1% of heavily treated persons. Together with TAMs, they confer high-level resistance to AZT, d4T, ddI, ABC, and TDF, and intermediate/high-level resistance to 3TC and FTC.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS71d_NRTI">
                <TEXT>Amino acid deletions (d) between codons 66 to 71 are rare and usually occur in combination with either multiple TAMs, the Q151M mutation complex, or K65R. Deletions that are closer to position 67 are more often associated with multiple TAMs. Deletions that are closest to position 69 are more often associated with the Q151M complex or K65R.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS71i_NRTI">
                <TEXT>Double amino acid insertions (i) between codons 66 to 71 most often align to codon 69 and occur in less than 1% of heavily treated persons. Together with TAMs, they confer high-level resistance to AZT, d4T, ddI, ABC, and TDF, and intermediate/high-level resistance to 3TC and FTC.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS74ACDEFGHKMNPQRSTWYdi_NRTI">
                <TEXT>L74VI reduce susceptibility to ddI and ABC. L74V increases AZT and TDF susceptibility in vitro but the clinical significance of this interaction is uncertain. L74I is occasionally selected by TDF. In contrast toL74V, L74I does not increase AZT or TDF susceptibility $listMutsIn{74ACDEFGHKMNPQRSTWYdi} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS74IV_NRTI">
                <TEXT>L74VI reduce susceptibility to ddI and ABC. L74V increases AZT and TDF susceptibility in vitro but the clinical significance of this interaction is uncertain. L74I is occasionally selected by TDF. In contrast toL74V, L74I does not increase AZT or TDF susceptibility.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS75CDEFGHKNPQRWYdi_NRTI">
                <TEXT>V75MTASI are NRTI-selected mutations. $listMutsIn{75CDEFGHKNPQRWYdi} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS75I_NRTI">
                <TEXT>V75I increases multinucleoside resistance caused by Q151M when present with F77L and F116Y.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS75M_NRTI">
                <TEXT>V75M is selected primarily by d4T and appears to reduce susceptibility to d4T, ddI, and possibly other NRTIs.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS75SAL_NRTI">
                <TEXT>V75SAL are non-polymorphic mutations that are weakly selected by NRTIs and may  decrease ddI and d4T susceptibility.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS75T_NRTI">
                <TEXT>V75T is a non-polymorphic mutation selected by d4T and ddI. It reduces susceptibilities to these NRTIs and possibly ABC.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS77ACDEGHIKMNPQRSTVWYdi_Other">
                <TEXT>F77L increases multinucleoside resistance caused by Q151M when present with V75I or F116Y. $listMutsIn{77ACDEGHIKMNPQRSTVWYdi} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS77L_NRTI">
                <TEXT>F77L increases multinucleoside resistance caused by Q151M when present with V75I or F116Y.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS90I_NNRTI">
                <TEXT>V90I is a polymorphic accessory mutation that is weakly selected by each of the NNRTIs in vitro and/or in vivo. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, reduction in NNRTI susceptibility.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS98G_NNRTI">
                <TEXT>A98G is a nonpolymorphic accessory mutation that reduces NVP and EFV susceptibility by about 5-fold and 3-fold, respectively. In combination with other mutations it is associated with reduced ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS100ACDEFGHKMNPQRSTVWYdi_NNRTI">
                <TEXT>L100I usually occurs in combination with K103N and in this setting it causes high-level NVP and EFV resistance and intermediate ETR and RPV resistance (>5-fold reduced susceptibility). L100V is an extremely rare nonpolymorphic mutation associated with reduced susceptibility to EFV, ETR, NVP, and possibly RPV. $listMutsIn{100ACDEFGHKMNPQRSTVWYdi} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS100I_NNRTI">
                <TEXT>L100I usually occurs in combination with K103N and in this setting it causes high-level NVP and EFV resistance and intermediate ETR and RPV resistance (>5-fold reduced susceptibility). It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS100V_NNRTI">
                <TEXT>L100V is an extremely rare nonpolymorphic mutation associated with reduced susceptibility to EFV, ETR, NVP, and possibly RPV.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS101ACDFGILMSTVWYdi_Other">
                <TEXT>$listMutsIn{101ACDFGILMSTVWYdi} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS101E_NNRTI">
                <TEXT>K101E causes intermediate resistance to NVP (5 to 10-fold reduced susceptibility) and low-level resistance to EFV, ETR, and RPV (2 to 5-fold reduced susceptibility). It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. In combination, with M184I, it reduces RPV susceptibility by 5-fold and has been associated with virological failure.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS101H_NNRTI">
                <TEXT>K101H is a nonpolymorphic mutation selected by NVP, EFV, and ETR. It contributes reduced susceptibility to these NNRTIs when present with other NNRTI-resistance mutations. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS101N_Other">
                <TEXT>K101N is a an uncommon nonpolymorphic NNRTI-selected mutation of uncertain phenotypic and clinical significance.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS101P_NNRTI">
                <TEXT>K101P causes high-level (>25-fold reduced susceptibility) to NVP, EFV, and RPV and intermediate resistance to ETR (>5-fold reduced susceptibility). It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS101Q_Other">
                <TEXT>K101Q is a relatively nonpolymorphic mutation that is weakly selected in patients receiving NNRTIs. It may contribute to reduced NVP, EFV, and ETR susceptibility when present with other NNRTI-resistance mutations.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS101R_Other">
                <TEXT>K101R is an uncommon polymorphism that is not associated with decreased NNRTI susceptibility.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS103ACDFGILMPVWYdi_NNRTI">
                <TEXT>K103NSTH are NNRTI-resistance mutations. K103REQ are variants that do not cause NNRTI resistance. $listMutsIn{103ACDFGILMPVWYdi} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS103EQ_NNRTI">
                <TEXT>K103EQ are rare mutations that have not been associated with decreased susceptibility to the current NNRTIs.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS103H_NNRTI">
                <TEXT>K103H is a rare mutation that is associated with 10 to 20-fold decreased susceptibility to NVP and EFV</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS103N_NNRTI">
                <TEXT>K103N causes high-level resistance to NVP (~50-fold reduced susceptibility) and EFV (~20-fold reduced susceptibility). it has no effect on ETR or RPV susceptibility.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS103R_Other">
                <TEXT>K103R is a polymorphic mutation that by itself has no effect on NNRTI susceptibility. However, in combination with V179D it reduces NVP and EFV susceptibility >10-fold.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS103S_NNRTI">
                <TEXT>K103S causes intermediate/high-level resistance to NVP (>10-fold reduced susceptibility) and low/intermediate-level resistance to EFV (~5-fold reduced susceptibility). Because K103S is a 2-bp change from the wildtype K, patients with K103S may be more likely to harbor K103N which is just a 1-bp change from wildtype.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS103T_NNRTI">
                <TEXT>K103T is a rare mutation that appear to be associated with >10-fold reduced NVP susceptibility but little if any effect on the remaining NNRTIs.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS106A_NNRTI">
                <TEXT>V106A causes high-level resistance to NVP (~50-fold reduced susceptibility) and intermediate resistance to EFV (5-to-fold reduced susceptibility). V106A + F227L cause high-level resistance to both NVP and EFV.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS106CDEFGHKLNPQRSTWYdi_Other">
                <TEXT>V106AM are NNRTI-resistance mutations. $listMutsIn{106CDEFGHKLNPQRSTWYdi} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS106I_NNRTI">
                <TEXT>V106I is a polymorphic accessory mutation that is weakly selected by EFV. In combination with V179D, it contributes reduced susceptibility to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS106M_NNRTI">
                <TEXT>V106M causes high-level resistance to NVP and EFV.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS108ACDEFGHKLMNPQRSTWYdi_Other">
                <TEXT>V108I reduces NVP and EFV susceptibility about 2-fold. $listMutsIn{108ACDEFGHKLMNPQRSTWYdi} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS108I_NNRTI">
                <TEXT>V108I is a relatively nonpolymorphic accessory mutation that is selected in vivo by NVP, EFV, and ETR. It reduces NVP and EFV susceptibility about 2-fold but does not appear to reduce ETR or RPV susceptibility.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS115ACDEGHIKLMNPQRSTVWdi_Other">
                <TEXT>Y115F causes intermediate resistance to ABC and low-level resistance to TDF. $listMutsIn{115ACDEGHIKLMNPQRSTVWdi} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS115F_NRTI">
                <TEXT>Y115F causes intermediate resistance to ABC and low-level resistance to TDF.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS116ACDEGHIKLMNPQRSTVWdi_Other">
                <TEXT>F116Y increases multinucleoside resistance caused by Q151M when present with F77L or V75I. $listMutsIn{116ACDEGHIKLMNPQRSTVWdi} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS116Y_NRTI">
                <TEXT>F116Y increases multinucleoside resistance caused by Q151M when present with F77L or V75I.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS118I_Other">
                <TEXT>V118I is a slightly polymorphic accessory NRTI-resistance mutation that occurs in combination with multiple TAMs.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS132ML_Other">
                <TEXT>I132M is an extremely rare mutation that has been reported to reduce NVP and EFV susceptibility in biochemical assays. I132L is a more common, nonpolymorphic, NNRTI-selected mutation that has not been characterized in vitro.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS138A_NNRTI">
                <TEXT>E138A is a common polymorphic accessory mutation. It is not selected by NVP and EFV but may be weakly selected by ETR and RPV. It decreases susceptibility to RPV and ETR by ~2-fold.  It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS138CDFHILMNPSTVWYdi_Other">
                <TEXT>E138K is associated with clinically decreased susceptibility to RPV and minimal phenotypic decreased susceptibility to each of the remaining NNRTIs. E138AKQ are poorly characterized ETR selected mutations. $listMutsIn{138CDFHILMNPSTVWYdi} is an unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS138GQR_NNRTI">
                <TEXT>E138QG are non-polymorphic accessory mutations frequently selected by ETR and/or RPV and occasionally selected by NVP and EFV. E138QG are associated with 2 to 3-fold decreased susceptibility to ETR and RPV. E138R is a rare non-polymorphic accessory mutations selected in vitro by RPV and associated with 2 to 3-fold decreased susceptibility to ETR and RPV.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS138K_NNRTI">
                <TEXT>E138K is a nonpolymorphic mutation that is selected commonly by RPV. By itself it reduces RPV susceptibility 2 to 3-fold. In combination with the NRTI-resistance mutation M184I, E138K reduces RPV susceptibility 5 to 7-fold. The combination of E138K + M184I appears sufficient to cause virological failure on an RPV-containing regimen. E138K causes low-level cross-resistance to ETR but minimal, if any cross-resistance to NVP and EFV.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS151ACDEFGHIKNPRSTVWYdi_Other">
                <TEXT>Q151M causes intermediate-to-high level resistance to AZT, ddI, d4T, and ABC; and low-level resistance to TDF, 3TC, and FTC.  In combination with mutations at its associated positions 75, 77, and 116, Q151M confers high-level resistance to AZT, ddI, d4T, and ABC; and  intermediate resistance to TDF, 3TC, and FTC. Q151L is an extremely rare transitional mutation that may precede the emergence of the Q151M. $listMutsIn{151ACDEFGHIKNPRSTVWYdi} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS151L_NRTI">
                <TEXT>Q151M causes intermediate-to-high level resistance to AZT, ddI, d4T, and ABC; and low-level resistance to TDF, 3TC, and FTC.  In combination with mutations at its associated positions 75, 77, and 116, Q151M confers high-level resistance to AZT, ddI, d4T, and ABC; and  intermediate resistance to TDF, 3TC, and FTC. Q151L is an extremely rare transitional mutation that may precede the emergence of the Q151M.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS151M_NRTI">
                <TEXT>Q151M causes intermediate-to-high level resistance to AZT, ddI, d4T, and ABC; and low-level resistance to TDF, 3TC, and FTC.  In combination with mutations at its associated positions 75, 77, and 116, Q151M confers high-level resistance to AZT, ddI, d4T, and ABC; and  intermediate resistance to TDF, 3TC, and FTC.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS179ACGHKMNPQRSWYdi_Other">
                <TEXT>$listMutsIn{V179ACGHKMNPQRSWYdi} is an unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS179DE_NNRTI">
                <TEXT>V179D is a slightly polymorphic accessory EFV-selected mutation. It reduces EFV susceptibility by 2 to 5-fold and has a lesser effect on NVP and ETR susceptibility. The combination of K103R + V179D decreases NVP and EFV susceptibility >10-fold and the combination of  V106I + V179D is also synergistic at reducing NVP and EFV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a nonpolymorphic mutation weakly selected by NVP and EFV and associated with slightly reduced NVP, EFV, and ETR susceptibility.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS179F_NNRTI">
                <TEXT>V179F nearly always occurs in combination with Y181C and is frequently selected for by ETR. By itself, V179F has no effect on ETR or RPV susceptibility but in combination with Y181C, it causes high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS179I_Other">
                <TEXT>V179I is a common polymorphism is often selected by ETR and RPV salvage therapy. It has not been shown to reduce NNRTI susceptibility.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS179L_NNRTI">
                <TEXT>V179L is a rare accessory mutation that is weakly selected by NNRTIs. It is listed as an RPV-associated mutation in the Edurant package insert.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS179T_NNRTI">
                <TEXT>V179T is a rare nonpolymorphic mutation that does not appear to be selected by NNRTIs or to reduce NNRTI susceptibility. But it has a weight of 1.0 in the Tibotec ETR GSS.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS181ADEHKLMNPQRTWdi_NNRTI">
                <TEXT>Y181C/I/V are associated with intermediate/high-level resistance to NVP, ETR, and RPV.  $listMutsIn{181(NOT CIVFSG)} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS181C_NNRTI">
                <TEXT>Y181C is a nonpolymorphic mutation frequently selected by NVP and ETR, and less commonly by RPV and EFV. Y181C reduces NVP, ETR, RPV, and EFV susceptibility by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C barely reduces EFV susceptibility, it is generally considered to be associated with a reduced response to treatment with an EFV-containing regimen. Preliminary data suggests that viruses containing Y181C by standard sequencing may harbor additional minority variants that render EFV less effective. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS181FSG_NNRTI">
                <TEXT>Y181F/S/G are rare nonpolymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V. They also may represent partial revertant mutations.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS181IV_NNRTI">
                <TEXT>Y181I/V are nonpolymorphic 2-base pair mutations selected by NVP and ETR. Y181I/V cause high-level NVP resistance and 10 to 15-fold reduced ETR and RPV susceptibility. Y181I/V each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS184ACDEFGHKLNPQRSTWYdi_NRTI">
                <TEXT>M184V/I cause high-level resistance to 3TC and FTC and low-level resistance to ddI and ABC. M184V/I are not contraindications to continued treatment with 3TC or FTC because these NRTIs increase susceptibility to AZT, TDF, and d4T and are associated with clinically significant decreased HIV-1 replication. In combination with K101E or E138K, M184I synergistically reduces RPV susceptibility. $listMutsIn{184ACDEFGHKLNPQRSTWYdi} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS184VI_NRTI">
                <TEXT>M184VI cause high-level resistance to 3TC and FTC and low-level resistance to ddI and ABC. M184VI are not contraindications to continued treatment with 3TC or FTC because these NRTIs increase susceptibility to AZT, TDF, and d4T and are associated with clinically significant decreased HIV-1 replication. In combination with K101E or E138K, M184I synergistically reduces RPV susceptibility.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS188ADEGIKMNPQRSTVWdi_NNRTI">
                <TEXT>Y188L/H/C are NNRTI-resistance mutations. $listMutsIn{188ADEGIKMNPQRSTVWdi} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS188C_NNRTI">
                <TEXT>Y188C is selected by NVP and EFV and confers high-level resistance (>25-fold reduced susceptibility) to NVP and EFV.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS188F_NNRTI">
                <TEXT>Y188F is a rare nonpolymorphic NNRTI-associated mutations that is usually present as part of an electrophoretic mixture. It is likely to represent a transitional mutation between Y and L. It also may represent a partial revertant mutation.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS188H_NNRTI">
                <TEXT>Y188H is selected by NVP and EFV and appears to cause intermediate / high-level resistance to NVP and low / intermediate-level resistance to EFV</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS188L_NNRTI">
                <TEXT>Y188L causes high-level resistance (>50-fold reduced susceptibility) to NVP and EFV, 5-fold decreased RPV susceptibility, and variable low-level reductions in ETR susceptibility.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS190A_NNRTI">
                <TEXT>G190A causes high level resistance to NVP and intermediate resistance to EFV. It does not reduce ETR susceptibility in vitro but it has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS190CTV_NNRTI">
                <TEXT>G190CTV are rare mutations that cause high-level resistance to NVP and EFV(>50-fold reduced susceptibility). Their effects on ETR and RPV are not known.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS190DFHIKLMNPRWYdi_NNRTI">
                <TEXT>G190ASEQTVC are NNRTI-resistance mutations. $listMutsIn{190DFHIKLMNPRWYdi} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS190EQ_NNRTI">
                <TEXT>G190EQ cause high-level resistance to NVP and EFV (>50-fold reduced susceptibility). Both mutations are selected by ETR and RPV in vitro. Preliminary data suggest that G190E and possibly G190Q cause >10-fold reduced ETR and RPV susceptibility.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS190S_NNRTI">
                <TEXT>G190S causes high-level resistance (>50-fold reduced susceptibility) to NVP and EFV. It does not reduce ETR susceptibility in vitro but it has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS210ACDEGHIKMNPQRTVYdi_Other">
                <TEXT>L210W contributes resistance to each of the NRTIs except 3TC and FTC. It usually occurs in combination with M41L and T215Y. $listMutsIn{210(NOT FSW)} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS210W_NRTI">
                <TEXT>L210W contributes resistance to each of the NRTIs except 3TC and FTC. It usually occurs in combination with M41L and T215Y.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS210W_Other">
                <TEXT>L210FS are rare mutations that are not associated with NRTI-resistance.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS215F_NRTI">
                <TEXT>T215F causes AZT and d4T resistance and reduces susceptibility to ABC, ddI, and TDF particularly in combination with M41L and L210W. T215F occurs more commonly (than T215Y) with Type II TAMs (D67N, K70R, and/or K219E) and in this context, it has a lesser effect on TDF, ABC, and ddI susceptibility compared with T215Y.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS215GHKMPQRWdi_NRTI">
                <TEXT>T215YF cause AZT and D4T resistance and reduce susceptibility to ABC, ddI, and TDF. T215SCDEIVALN do not decrease NRTI susceptibility but arise from viruses that once contained T215YF. $listMutsIn{215(NOT CDEFISVY)} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS215SCDEIVALN_NRTI">
                <TEXT>T215Y/F cause AZT and D4T resistance and reduce susceptibility to ABC, ddI, and TDF. T215S/C/D/E/I/V do not decrease NRTI susceptibility but arise from viruses that once contained T215Y/F.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS215Y_NRTI">
                <TEXT>T215Y causes AZT and d4T resistance and reduces susceptibility to ABC, ddI, and TDF particularly in combination with M41L and L210W.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS219ACDFGHILMPSTVYdi_Other">
                <TEXT>K219QENRW are NRTI-associated mutations. $listMutsIn{219ACDFGHILMPSTVYdi} is an unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS219NR_NRTI">
                <TEXT>K219NR are non-polymorphic NRTI-selected mutations that occur in combination with multiple TAMs.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS219QE_NRTI">
                <TEXT>K219QE is an NRTI-selected mutation selected by AZT and d4T. It decreases susceptibility to these NRTIs when it occurs in combination with K70R or T215YF but has little if any effect on the remaining NRTIs.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS219W_NRTI">
                <TEXT>K219W is an uncommon NRTI-selected mutations.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS221ACDEFGIKLMNPQRSTVWdi_Other">
                <TEXT>H221Y is a nonpolymorphic accessory NNRTI-selected mutation which frequently occurs in combination with Y181C. It has minimal, if any, effects on NNRTI susceptibility.   $listMutsIn{221ACDEFGIKLMNPQRSTVWdi} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS221Y_NNRTI">
                <TEXT>H221Y is a nonpolymorphic accessory NNRTI-selected mutation which frequently occurs in combination with Y181C. It has minimal, if any, effects on NNRTI susceptibility. It is listed as an RPV-associated mutation in the Edurant package insert.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS225ACDEFGIKLMNQRSTVWYdi_Other">
                <TEXT>P225H increases EFV resistance in combination with K103N. $listMutsIn{225ACDEFGIKLMNQRSTVWYdi} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS225H_NNRTI">
                <TEXT>P225H is a nonpolymorphic EFV-selected mutation that increases EFV resistance in combination with K103N.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS227ADEGHIKMNPQRSTVWYdi_Other">
                <TEXT>F227LC are NNRTI-associated mutations. $listMutsIn{F227ADEGHIKMNPQRSTVWYdi} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS227C_NNRTI">
                <TEXT>F227C is an extremely rare nonpolymorphic mutation which  emerges in vitro under ETR and RPV selection pressure. It usually occurs in combination with other NNRTI-resistance mutations and in this context it is associated with high-level resistance to each of the NNRTIs.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS227L_NNRTI">
                <TEXT>F227L usually occurs in combination with V106A and in this setting is associated with high level resistance to NVP and EFV.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS230ACDEFGHIKNPQRSTVWYdi_Other">
                <TEXT>M230L causes intermediate-to-high-level resistance to each of the NNRTIs. $listMutsIn{230ACDEFGHIKNPQRSTVWYdi} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS230L_NNRTI">
                <TEXT>M230L is an uncommon nonpolymorphic mutation selected by NVP and EFV. It reduces NVP and EFV susceptibility by 10-20-fold. It has been selected in vitro by ETR and reduces ETR susceptibility by ~3 to 10-fold. M230L is selected by RPV in vitro and in vivo but its effect on RPV susceptibility has not yet been reported. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS236ACDEFGHIKMNQRSTVWYdi_Other">
                <TEXT>P236L causes high-level DLV resistance but does not decrease the susceptibility of any other NNRTIs. $listMutsIn{236ACDEFGHIKMNQRSTVWYdi} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS236L_NNRTI">
                <TEXT>P236L causes high-level DLV resistance but does not decrease the susceptibility of any other NNRTIs.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS238ACDEFGHILMPQSVWYdi_Other">
                <TEXT>K238TN are nonpolymorphic NNRTI-associated mutations. K238R is a common polymorphism that is not associated with NNRTIs. $listMutsIn{238ACDEFGHILMPQSVWYdi} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS238R_Other">
                <TEXT>K238R is a common polymorphism that does not reduce NNRTI susceptibility.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS238TN_NNRTI">
                <TEXT>K238T/N are nonpolymorphic NVP and ETR-selected mutations that usually occur in combination with K103N.K238N occurs less commonly than K238T and contributes less to reduced NNRTI susceptibility compared with NVP and EFV.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS318ACDEGHIKLMNPQRSTVWdi_Other">
                <TEXT>Y318F is an uncommon mutation that causes intermediate-level NVP resistance and potentially low-level EFV resistance. It is selected in vitro by ETR. $listMutsIn{318ACDEGHIKLMNPQRSTVWdi} is a highly unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS318F_NNRTI">
                <TEXT>Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It is also selected in vitro by ETR.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS348ACDEFGHKLMPQRSTVWYdi_Other">
                <TEXT>N348I is a nonpolymorphic accessory NNRTI-selected mutation. By itself, N348I reduces NVP and EFV susceptibility by 2-3-fold. $listMutsIn{348ACDEFGHKLMPQRSTVWYdi} is an unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="RT_POS348I_NNRTI">
                <TEXT>N348I is a nonpolymorphic accessory NNRTI-selected mutation. By itself, N348I reduces NVP and EFV susceptibility by 2-3-fold.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>
<!-- End the RT mutation-dependent comment strings. -->

<!-- Begin the IN mutation-dependent comment strings. -->
            <COMMENT_STRING id="IN_POS51ACDEFGIKLMNPQRSTVWdi_Accessory">
                <TEXT>$listMutsIn{51ACDEFGIKLMNPQRSTVWdi} is an unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS51Y_Accessory">
                <TEXT>H51Y is a nonpolymorphic mutation that is selected in vitro by EVG and DTG and in vivo by RAL and EVG. It reduces EVG susceptibility by about 2-3-fold but does not appear to reduce RAL or DTG susceptibility.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS66A_Major">
                <TEXT>T66A is a nonpolymorphic mutation selected in vivo by EVG and RAL usually in combination with other INI-resistance mutations. It causes >5-fold reductions in EVG susceptibility but does not appear to reduce RAL or DTG susceptibility.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS66CDEFGHLMNPQRSVWYdi_Major">
                <TEXT>$listMutsIn{66CDEFGHLMNPQRSVWYdi} is an unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS66I_Major">
                <TEXT>T66I is a nonpolymorphic mutation selected in vitro and in vivo by EVG.  T66I decreases EVG susceptibility by ~10-fold  but does not reduce RAL or DTG susceptibility.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS66K_Major">
                <TEXT>T66K is a nonpolymorphic mutation selected in vitro and in vivo by EVG. It is associated with 40-80-fold decreased EVG susceptibility, 10-20-fold decreased RAL susceptibility and 2-fold decreased DTG susceptibility.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS68VI_Accessory">
                <TEXT>L68VI are polymorphic accessory mutations selected in vivo by EVG. In combination with E92Q, they further reduce EVG susceptibility.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS74M_Accessory">
                <TEXT>L74M is a polymorphic accessory INI-resistance mutation selected by RAL. It does not decrease INI susceptibility alone but decreases RAL susceptibility in combination with N155H. L74M also appears to be selected by DTG in patients previously treated with RAL.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS92ACDFHIKLMNPRSTWYdi_Major">
                <TEXT>$listMutsIn{92(NOT GQV)} is an unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS92G_Major">
                <TEXT>E92G is a nonpolymorphic mutation selected in vitro  and in vivo by EVG. It reduces EVG susceptibility ~10-fold but does not reduce RAL or DTG susceptibility.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS92Q_Major">
                <TEXT>E92Q is a nonpolymorphic mutation selected in patients receiving RAL and EVG. It reduces RAL susceptibility by ~5-fold  and EVG susceptibility by ~30-fold depending on the assay and genetic context. It is often the primary mutation associated with virological failure on an EVG-containing regimen. It is selected in vitro by DTG and reduces DTG susceptibility by ~1.5-fold.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS92V_Major">
                <TEXT>E92V emerges during in vitro passage with the investigational INI GS-9160. It reduces RAL and EVG susceptibility 10 and 40-fold, respectively. It has not been reported in patients receiving RAL or EVG.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS95ACDEFGHILMNPRSTVWYdi_Other">
                <TEXT>$listMutsIn{95ACDEFGHILMNPRSTVWYdi} is an unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS95K_Accessory">
                <TEXT>Q95K is a nonpolymorphic accessory INI-resistance mutation selected in vitro by EVG and in vivo by RAL. It does not appear to be associated with significantly reduced INI susceptibility.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS97A_Accessory">
                <TEXT>T97A is a minimally polymorphic accessory INI-resistance mutation selected by RAL and EVG often in combination with Y143 mutations. By itself, it has minimal if any effect on INI susceptibility but it markedly reduces RAL susceptibility in combination with Y143CR. T97A also appears to be selected by DTG in patients previously treated with RAL.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS97CDEFGHIKLMNPQRSVWYdi_Accessory">
                <TEXT>T97A is a minimally polymorphic accessory INI-resistance mutation selected by RAL and EVG often in combination with Y143 mutations. By itself, it has minimal if any effect on INI susceptibility but it markedly reduces RAL susceptibility in combination with Y143CR. T97A also appears to be selected by DTG in patients previously treated with RAL. $listMutsIn{95(NOT A)} is an unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS114ACDEFGIKLMNPQRSTVWdi_Other">
                <TEXT>$listMutsIn{114ACDEFGIKLMNPQRSTVWdi} is an unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS114Y_Accessory">
                <TEXT>H114Y is an extremely rare nonpolymorphic mutation selected in vitro by EVG. It does not appear to be associated with significantly reduced INI susceptibility.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS118ACDEFHIKLMNPQSTVWYdi_Accessory">
                <TEXT>$listMutsIn{118ACDEFHIKLMNPQSTVWYdi} is an unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS118R_Major">
                <TEXT>G118R is an extremely rare nonpolymorphic mutation that has been selected in a CRF02_AG-infected patient receiving RAL. In combination with L74M the virus was found to have ~10-fold decreased susceptibility to RAL and variable lower levels of decreased susceptibility to EVG. G118R has been selected in vitro by DTG but causes little if any reduction in DTG susceptibility.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS121ACDEGHIKLMNPQRSTVWdi_Accessory">
                <TEXT>$listMutsIn{121ACDEGHIKLMNPQRSTVWdi} is an unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS121Y_Major">
                <TEXT>F121Y is a nonpolymorphic mutation that is selected in vitro by RAL and EVG and rarely in vivo by RAL. It reduces susceptibility to RAL and EVG by about 5 and 10-fold, respectively.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS128CDEFGHIKLMNPQRSVWYdi_Other">
                <TEXT>$listMutsIn{128CDEFGHIKLMNPQRSVWYdi} is an unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS128T_Accessory">
                <TEXT>A128T is a nonpolymorphic mutation selected in vitro by EVG  but it does not appear to be associated with significantly reduced INI susceptibility.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS138CDFGHILMNPQRSTVWYdi_Accessory">
                <TEXT>$listMutsIn{138CDFGHILMNPQRSTVWYdi} is an unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS138KA_Accessory">
                <TEXT>E138KA are nonpolymorphic accessory resistance mutations selected in patients receiving RAL, EVG, and DTG usually in combination with Q148 mutations. Alone they do not reduce INI susceptibility but in combination with Q148 mutations they reduce RAL and EVG susceptibility >100-fold and DTG susceptibility ~10-fold.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS140DEFHIKLMNPQRTVWYdi_Accessory">
                <TEXT>G140S is a nonpolymorphic mutation that usually occurs with Q148HRK in patients receiving RAL or EVG. By itself it does not reduce INI susceptibility. However, in combination with Q148HRK, it reduces RAL and EVG susceptibility >100-fold and DTG ~10-fold. G140AC are less well-studied variants that appear to have effects similar to G140S. $listMutsIn{140DEFHIKLMNPQRTVWYdi} is an unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS140SAC_Accessory">
                <TEXT>G140S is a nonpolymorphic mutation that usually occurs with Q148HRK in patients receiving RAL or EVG. By itself it does not reduce INI susceptibility. However, in combination with Q148HRK, it reduces RAL and EVG susceptibility >100-fold and DTG ~10-fold. G140AC are less well-studied variants that appear to have effects similar to G140S.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS143ADEFGILMNPQSTVWdi_Major">
                <TEXT>Y143CR are nonpolymorphic mutations selected by RA.L Alone Y143C and Y143R reduce RAL susceptibility by ~5 and 20-fold respectively but with T97A or other accessory mutations, they reduce RAL susceptibility >100-fold. Y143 mutations have no effect on EVG or DTG susceptibility. Y143H is a less common mutation at this position that appears to represent a transition between Y and R.  $listMutsIn{143ADEFGILMNPQSTVWdi} is an unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS143CRHK_Major">
                <TEXT>Y143CR are nonpolymorphic mutations selected by RA.L Alone Y143C and Y143R reduce RAL susceptibility by ~5 and 20-fold respectively but with T97A or other accessory mutations, they reduce RAL susceptibility >100-fold. Y143 mutations have no effect on EVG or DTG susceptibility. Y143H is a less common mutation at this position that appears to represent a transition between Y and R. Y143K is an extremely rare RAL-associated mutation that confers about 10-fold reduced RAL susceptibility</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS145ACDEFGHIKLMNQRTVWYdi_Major">
                <TEXT>P145S is a nonpolymorphic mutation that has been selected in vitro by EVG and causes high-level resistance to EVG. $listMutsIn{145ACDEFGHIKLMNQRTVWYdi} is an unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS145S_Major">
                <TEXT>P145S is a nonpolymorphic mutation that has been selected in vitro by EVG and causes high-level resistance to EVG.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS146ACDEFGHIKLMNRSTVWYdi_Major">
                <TEXT>Q146P is a nonpolymorphic mutation that has been selected in vitro by EVG and shown to reduce EVG susceptibility about 10-fold. $listMutsIn{146ACDEFGHIKLMNRSTVWYdi} is an unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS146P_Major">
                <TEXT>Q146P is a nonpolymorphic mutation that has been selected in vitro by EVG and shown to reduce EVG susceptibility about 10-fold.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS147ACDEFHIKLMNPQRTVWYdi_Major">
                <TEXT>S147G is a nonpolymorphic mutation selected in patients receiving EVG. It reduces EVG susceptibility 5 to 10-fold. It does not reduce RAL or DTG susceptibility. $listMutsIn{147ACDEFHIKLMNPQRTVWYdi} is an unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS147G_Major">
                <TEXT>S147G is a nonpolymorphic mutation selected in patients receiving EVG. It reduces EVG susceptibility 5 to 10-fold. It does not reduce RAL or DTG susceptibility.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS148ACDEFGILMNPSTVWYdi_Major">
                <TEXT>Q148HKR are nonpolymorphic mutations selected by RAL and EVG.  By itself Q148H reduces RAL and EVG susceptibility about 5-10 fold and Q148RK reduce RAL and EVG susceptibility >30-100 fold. With G140S, Q148HRK reduce RAL and EVG susceptibility >100-fold.  Q148HKR alone have minimal effects on DTG susceptibility but cause >10-fold reduced susceptibility in combination with E138K +/- G140S. $listMutsIn{148ACDEFGILMNPSTVWYdi} is an unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS148HKR_Major">
                <TEXT>Q148HKR are nonpolymorphic mutations selected by RAL and EVG.  By itself Q148H reduces RAL and EVG susceptibility about 5-10 fold and Q148RK reduce RAL and EVG susceptibility >30-100 fold. With G140S, Q148HRK reduce RAL and EVG susceptibility >100-fold.  Q148HKR alone have minimal effects on DTG susceptibility but cause >10-fold reduced susceptibility in combination with E138K +/- G140S.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS151A_Accessory">
                <TEXT>V151A is an extremely rare nonpolymorphic mutation has been selected in vitro by an investigational INI. It has been associated with 4 and 12-fold reduced susceptibility to RAL and EVG, respectively.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS151CDEFGHKMNPQRSTWYdi_Other">
                <TEXT>$listMutsIn{151CDEFGHKMNPQRSTWYdi} is an unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS151I_Accessory">
                <TEXT>V151I is a polymorphic mutation selected in vitro by EVG and in vivo by RAL. It appears to have little or no effect on INI susceptibility.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS151L_Major">
                <TEXT>V151L is an extremely rare nonpolymorphic mutation has been selected in vitro by early investigational INIs but not in vivo with current INIs. It decreases susceptibility to RAL, EVG, and DTG by ~10, ~40, and 3.6-fold, respectively.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS153ACDEGHIKLMNPQRTVWdi_Other">
                <TEXT>$listMutsIn{153ACDEGHIKLMNPQRTVWdi} is an unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS153YF_Accessory">
                <TEXT>S153Y is a nonpolymorphic mutation selected in vitro by EVG and DTG. S153F is also selected in vitro by DTG. Each mutation reduces EVG and DTG susceptibility about 2-fold.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS155ACDEFGIKLMPQRVWYdi_Major">
                <TEXT>N155H is a nonpolymorphic mutation selected in patients receiving RAL and EVG. By itself, it decreases RAL susceptibility about 10-fold and EVG susceptibility ~30-fold. Susceptibility is further decreased in combination with E92Q and other primary or accessory INI-resistance mutations. N155H may be selected by DTG in RAL-experienced patients.N155ST are uncommon nonpolymorphic INI-resistance mutations that decrease RAL and EVG susceptibility somewhat less than that of N155H.  $listMutsIn{155(NOT HS)} is an unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS155H_Major">
                <TEXT>N155H is a nonpolymorphic mutation selected in patients receiving RAL and EVG. By itself, it decreases RAL susceptibility ~10-fold and EVG susceptibility ~30-fold. Susceptibility is further decreased in combination with E92Q and other primary or accessory INI-resistance mutations. N155H may be selected by DTG in RAL-experienced patients.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS155ST_Major">
                <TEXT>N155ST are uncommon nonpolymorphic INI-resistance mutations that decrease RAL and EVG susceptibility somewhat less than that of N155H.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS157ACDFGHIKLMNPRSTVWYdi_Other">
                <TEXT>E157Q is a minimally polymorphic mutation that is selected in vitro by EVG and possibly in vivo by RAL. It appears to minimally reduce RAL and EVG susceptibility. $listMutsIn{157ACDFGHIKLMNPRSTVWYdi} is an unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS157Q_Accessory">
                <TEXT>E157Q is a minimally polymorphic mutation that is selected in vitro by EVG and possibly in vivo by RAL. It appears to minimally reduce RAL and EVG susceptibility.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS163RK_Accessory">
                <TEXT>G163RK are relatively nonpolymorphic accessory INI-resistance mutation that usually occur in combination with other INI-resistance mutations in patients receiving RAL.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS230R_Accessory">
                <TEXT>S230R is a nonpolymorphic mutation that is selected in vitro and in vivo by RAL (Blanco, 2011) and in vitro by EVG. It appears to have minimal if any effect on INI susceptibility.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS263ACDEFGHILMNPQSTVWYdi_Other">
                <TEXT>R263K is a nonpolymorphic mutation selected in vitro by EVG and DTG and in vivo by RAL. It reduces DTG and EVG susceptibility ~2-fold and 6-fold, respectively in the PhenoSense assay but has minimal if any effect on RAL susceptibility.  $listMutsIn{263ACDEFGHILMNPQSTVWYdi} is an unusual mutation at this position.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>

            <COMMENT_STRING id="IN_POS263K_Accessory">
                <TEXT>R263K is a nonpolymorphic mutation selected in vitro by EVG and DTG and in vivo by RAL. It reduces DTG and EVG susceptibility ~2-fold and 6-fold, respectively in the PhenoSense assay but has minimal if any effect on RAL susceptibility.</TEXT>
                <SORT_TAG>1</SORT_TAG>
            </COMMENT_STRING>
<!-- End the IN mutation-dependent comment strings. -->

	</COMMENT_DEFINITIONS>
    </DEFINITIONS>

    <DRUG>
        <NAME>RPV</NAME>
        <FULLNAME>rilpivirine</FULLNAME>
        <RULE>
            <CONDITION>
                SCORE FROM (98G => 5,
                            MAX ( 100I => 30, 100V => 15 ),
                            MAX ( 101P => 60, 101E => 30, 101H => 10 ),
                            MAX ( 138K => 30, 138GQR => 15, 138A => 5 ),
                            MAX ( 179F => 15, 179DELT => 5 ),
                            MAX ( 181IV => 60, 181C => 30, 181FGS => 15 ),
                            MAX ( 188L => 60, 188F => 30 ),
                            MAX ( 190EQ => 45, 190ACSTV => 10 ),
                            221Y => 5,
                            227C => 30,
                            230IL => 30,
                            (101E AND 184I) => 30,
                            (106I AND 179D) => 5,
                            (106I AND 181C) => 5,
                            (138K AND 184I) => 30,
                            (181C AND 190ASCVT) => 10,
                            (181C AND 221Y) => 5,
                            (181CIV AND 179F) => 15,
                            (90I AND 181C) => 5
                           )
            </CONDITION>
            <ACTIONS>
                <SCORERANGE><USE_GLOBALRANGE/></SCORERANGE>
            </ACTIONS>
        </RULE>
    </DRUG>

    <DRUG>
        <NAME>EFV</NAME>
        <FULLNAME>efavirenz</FULLNAME>
        <RULE>
            <CONDITION>
                SCORE FROM (98G => 5,
                            MAX ( 100I => 45, 100V => 30 ),
                            MAX ( 101P => 60, 101E => 15, 101H => 10 ),
                            MAX ( 103HN => 60, 103S => 45, 103T => 15 ),
                            MAX ( 106M => 60, 106A => 30 ),
                            108I => 5,
                            MAX ( 138K => 10, 138GQR => 5 ),
                            MAX ( 179DE => 10, 179F => 5 ),
                            MAX ( 181CIV => 30, 181FGS => 15 ),
                            MAX ( 188CFL => 60, 188H => 30 ),
                            MAX ( 190CEQSTV => 60, 190A => 45 ),
                            225H => 30,
                            MAX ( 227C => 30, 227L => 15 ),
                            MAX ( 230L => 30, 230I => 15 ),
                            MAX ( 238T => 15, 238N => 10 ),
                            318F => 10,
                            348I => 10,
                            (103R AND 179D) => 20,
                            (103R AND 179E) => 5,
                            (106A AND 227L) => 15,
                            (106I AND 179D) => 5
                           )
            </CONDITION>
            <ACTIONS>
                <SCORERANGE><USE_GLOBALRANGE/></SCORERANGE>
            </ACTIONS>
        </RULE>
    </DRUG>

    <DRUG>
        <NAME>NVP</NAME>
        <FULLNAME>nevirapine</FULLNAME>
        <RULE>
            <CONDITION>
                SCORE FROM (98G => 15,
                            MAX ( 100I => 45, 100V => 15 ),
                            MAX ( 101P => 60, 101E => 30, 101H => 15 ),
                            103HNST => 60,
                            106AM => 60,
                            108I => 10,
                            MAX ( 138K => 10, 138GQR => 5 ),
                            179DEF => 10,
                            181CFGISV => 60,
                            MAX ( 188CHL => 60, 188F => 30 ),
                            190ACEQSTV => 60,
                            221Y => 5,
                            225H => 15,
                            227CL => 30,
                            MAX ( 230L => 60, 230I => 30 ),
                            MAX ( 238T => 30, 238N => 10 ),
                            318F => 30,
                            348I => 15,
                            (103R AND 179D) => 20,
                            (103R AND 179E) => 5,
                            (106I AND 179D) => 5
                           )
            </CONDITION>
            <ACTIONS>
                <SCORERANGE><USE_GLOBALRANGE/></SCORERANGE>
            </ACTIONS>
        </RULE>
    </DRUG>

    <DRUG>
        <NAME>ETR</NAME>
        <FULLNAME>etravirine</FULLNAME>
        <RULE>
            <CONDITION>
                SCORE FROM (98G => 5,
                            MAX ( 100I => 30, 100V => 10 ),
                            MAX ( 101P => 45, 101EH => 10 ),
                            MAX ( 138GKQR => 10, 138A => 5 ),
                            MAX ( 179F => 15, 179DET => 5 ),
                            MAX ( 181IV => 60, 181C => 30, 181FGS => 15 ),
                            188L => 15,
                            MAX ( 190EQ => 45, 190ACSTV => 10 ),
                            227C => 30,
                            MAX ( 230L => 30, 230I => 15 ),
                            (106I AND 179D) => 5,
                            (106I AND 181C) => 5,
                            (181C AND 190ASCVT) => 10,
                            (181CIV AND 179F) => 15,
                            (90I AND 181C) => 5
                           )
            </CONDITION>
            <ACTIONS>
                <SCORERANGE><USE_GLOBALRANGE/></SCORERANGE>
            </ACTIONS>
        </RULE>

	<RULE>
	    <CONDITION>SELECT ATLEAST 1 FROM (90I,98G,100I,101EPH,106I,138A,179DFT,181CIV,190AS,230L)
            </CONDITION>
	    <ACTIONS>
	        <COMMENT ref="RT_ETR_Special" />
	    </ACTIONS>
	</RULE>
    </DRUG>

    <DRUG>
        <NAME>3TC</NAME>
        <FULLNAME>lamivudine</FULLNAME>
        <RULE>
            <CONDITION>
                SCORE FROM (40F => 5,
                            41L => 5,
                            44DA => 5,
                            62V => 5,
                            MAX ( 65R => 30, 65N => 15 ),
                            MAX ( 66i => 30, 66d => 15 ),
                            MAX ( 67i => 30, 67d => 15 ),
                            MAX ( 68i => 30, 68d => 15 ),
                            MAX ( 69i => 30, 69d => 15 ),
                            MAX ( 70i => 30, 70d => 15, 70GETSNQ => 10 ),
                            MAX ( 71i => 30, 71d => 15 ),
                            75I => 5,
                            77L => 5,
                            116Y => 5,
                            118I => 5,
                            MAX ( 151M => 15, 151L => 10 ),
                            184VI => 60,
                            210W => 5,
                            215YF => 5,
                            (118I AND 41L AND 215FY) => 5,
                            (40F AND 41L AND 215FY) => 5,
                            (44AD AND 41L AND 215FY) => 5
                           )
            </CONDITION>
            <ACTIONS>
                <SCORERANGE><USE_GLOBALRANGE/></SCORERANGE>
            </ACTIONS>
        </RULE>
    </DRUG>

    <DRUG>
        <NAME>FTC</NAME>
        <FULLNAME>emtricitabine</FULLNAME>
        <RULE>
            <CONDITION>
                SCORE FROM (40F => 5,
                            41L => 5,
                            44DA => 5,
                            62V => 5,
                            MAX ( 65R => 30, 65N => 15 ),
                            MAX ( 66i => 30, 66d => 15 ),
                            MAX ( 67i => 30, 67d => 15 ),
                            MAX ( 68i => 30, 68d => 15 ),
                            MAX ( 69i => 30, 69d => 15 ),
                            MAX ( 70i => 30, 70d => 15, 70GETSNQ => 10 ),
                            MAX ( 71i => 30, 71d => 15 ),
                            75I => 5,
                            77L => 5,
                            116Y => 5,
                            118I => 5,
                            MAX ( 151M => 15, 151L => 10 ),
                            184VI => 60,
                            210W => 5,
                            215YF => 5,
                            (118I AND 41L AND 215FY) => 5,
                            (40F AND 41L AND 215FY) => 5,
                            (44AD AND 41L AND 215FY) => 5
                           )
            </CONDITION>
            <ACTIONS>
                <SCORERANGE><USE_GLOBALRANGE/></SCORERANGE>
            </ACTIONS>
        </RULE>
    </DRUG>

    <DRUG>
        <NAME>ABC</NAME>
        <FULLNAME>abacavir</FULLNAME>
        <RULE>
            <CONDITION>
                SCORE FROM (40F => 5,
                            41L => 5,
                            44DA => 5,
                            62V => 5,
                            MAX ( 65R => 60, 65N => 15 ),
                            MAX ( 66i => 45, 66d => 30 ),
                            MAX ( 67i => 45, 67d => 30, 67EGSTHN => 5 ),
                            MAX ( 68i => 45, 68d => 30 ),
                            MAX ( 69i => 45, 69d => 15, 69G => 10 ),
                            MAX ( 70i => 45, 70GEd => 15, 70TSNQ => 10, 70R => 5 ),
                            MAX ( 71i => 45, 71d => 15 ),
                            74IV => 30,
                            MAX ( 75T => 15, 75I => 5 ),
                            77L => 5,
                            115F => 45,
                            116Y => 5,
                            118I => 5,
                            MAX ( 151M => 60, 151L => 30 ),
                            184VI => 15,
                            210W => 5,
                            MAX ( 215YF => 15, 215CDEIVSNAL => 10 ),
                            219QENRW => 5,
                            (118I AND 41L AND 215FY) => 5,
                            (184VI AND 74VI) => 15,
                            (210W AND 215FY) => 10,
                            (210W AND 215SCDEIVNAL) => 5,
                            (40F AND 41L AND 215FY) => 5,
                            (41L AND 210W) => 10,
                            (41L AND 215FY) => 10,
                            (41L AND 215SCDEIVNAL) => 5,
                            (44AD AND 41L AND 215FY) => 5,
                            (67NG AND 70R AND 219QENR) => 10
                           )
            </CONDITION>
            <ACTIONS>
                <SCORERANGE><USE_GLOBALRANGE/></SCORERANGE>
            </ACTIONS>
        </RULE>
    </DRUG>

    <DRUG>
        <NAME>AZT</NAME>
        <FULLNAME>zidovudine</FULLNAME>
        <RULE>
            <CONDITION>
                SCORE FROM (40F => 5,
                            41L => 15,
                            44DA => 5,
                            62V => 5,
                            MAX ( 65N AND EXCLUDE 65(NOT N) => -10, 65R AND EXCLUDE 65(NOT R) => -15 ),
                            MAX ( 66i => 45, 66d => 30 ),
                            MAX ( 67i => 45, 67d => 30, 67N => 15, 67EGSTH => 10 ),
                            MAX ( 68i => 45, 68d => 30 ),
                            MAX ( 69i => 45, 69N => 5 ),
                            MAX ( 70i => 45, 70R => 30, 70GE AND EXCLUDE 70(NOT GE) => -10 ),
                            71i => 45,
                            75I => 5,
                            77L => 5,
                            116Y => 5,
                            118I => 5,
                            MAX ( 151M => 60, 151L => 30 ),
                            184VI AND EXCLUDE 184(NOT VI) => -10,
                            210W => 15,
                            MAX ( 215YF => 45, 215CDEIVSNAL => 20 ),
                            219QENRW => 10,
                            348I => 10,
                            (118I AND 41L AND 215FY) => 5,
                            (210W AND 215FY) => 10,
                            (210W AND 215SCDEIVNAL) => 5,
                            (40F AND 41L AND 215FY) => 5,
                            (41L AND 210W) => 10,
                            (41L AND 215FY) => 10,
                            (41L AND 215SCDEIVNAL) => 5,
                            (44AD AND 41L AND 215FY) => 5,
                            (65R AND 151M) => 15,
                            (67NG AND 70R AND 219QENR) => 10
                           )
            </CONDITION>
            <ACTIONS>
                <SCORERANGE><USE_GLOBALRANGE/></SCORERANGE>
            </ACTIONS>
        </RULE>

    </DRUG>

    <DRUG>
        <NAME>D4T</NAME>
        <FULLNAME>stavudine</FULLNAME>
        <RULE>
            <CONDITION>
                SCORE FROM (40F => 5,
                            41L => 15,
                            44DA => 5,
                            62V => 5,
                            MAX ( 65R => 45, 65N => 30 ),
                            MAX ( 66i => 45, 66d => 30 ),
                            MAX ( 67i => 45, 67d => 30, 67N => 15, 67EGSTH => 10 ),
                            MAX ( 68i => 45, 68d => 30 ),
                            MAX ( 69i => 45, 69d => 15, 69DG => 10, 69N => 5 ),
                            MAX ( 70i => 45, 70GERd => 15, 70TSNQ => 10 ),
                            MAX ( 71i => 45, 71d => 15 ),
                            MAX ( 75T => 60, 75M => 40, 75ALS => 10, 75I => 5 ),
                            77L => 5,
                            116Y => 5,
                            118I => 5,
                            MAX ( 151M => 60, 151L => 30 ),
                            184VI AND EXCLUDE 184(NOT VI) => -10,
                            210W => 15,
                            MAX ( 215YF => 45, 215CDEIVSNAL => 20 ),
                            219QENRW => 10,
                            348I => 10,
                            (118I AND 41L AND 215FY) => 5,
                            (210W AND 215FY) => 10,
                            (210W AND 215SCDEIVNAL) => 5,
                            (40F AND 41L AND 215FY) => 5,
                            (41L AND 210W) => 10,
                            (41L AND 215FY) => 10,
                            (41L AND 215SCDEIVNAL) => 5,
                            (44AD AND 41L AND 215FY) => 5,
                            (65N AND 184VI) => 10,
                            (65R AND 184VI) => 10,
                            (67NG AND 70R AND 219QENR) => 10,
                            (70EG AND 184VI) => 10
                           )
            </CONDITION>
            <ACTIONS>
                <SCORERANGE><USE_GLOBALRANGE/></SCORERANGE>
            </ACTIONS>
        </RULE>
    </DRUG>

    <DRUG>
        <NAME>DDI</NAME>
        <FULLNAME>didanosine</FULLNAME>
        <RULE>
            <CONDITION>
                SCORE FROM (40F => 5,
                            41L => 5,
                            44DA => 5,
                            62V => 5,
                            MAX ( 65R => 60, 65N => 30 ),
                            MAX ( 66i => 45, 66d => 30 ),
                            MAX ( 67i => 45, 67d => 30, 67EGSTHN => 5 ),
                            MAX ( 68i => 45, 68d => 30 ),
                            MAX ( 69i => 45, 69D => 30, 69d => 15, 69GN => 10 ),
                            MAX ( 70i => 45, 70GEd => 15, 70TSNQ => 10, 70R => 5 ),
                            MAX ( 71i => 45, 71d => 15 ),
                            74IV => 60,
                            MAX ( 75T => 30, 75M => 15, 75ALS => 10, 75I => 5 ),
                            77L => 5,
                            116Y => 5,
                            118I => 5,
                            MAX ( 151M => 60, 151L => 30 ),
                            184VI => 10,
                            210W => 5,
                            MAX ( 215YF => 15, 215CDEIVSNAL => 10 ),
                            219QENRW => 5,
                            (118I AND 41L AND 215FY) => 5,
                            (210W AND 215FY) => 10,
                            (210W AND 215SCDEIVNAL) => 5,
                            (40F AND 41L AND 215FY) => 5,
                            (41L AND 210W) => 10,
                            (41L AND 215FY) => 10,
                            (41L AND 215SCDEIVNAL) => 5,
                            (44AD AND 41L AND 215FY) => 5,
                            (67NG AND 70R AND 219QENR) => 10
                           )
            </CONDITION>
            <ACTIONS>
                <SCORERANGE><USE_GLOBALRANGE/></SCORERANGE>
            </ACTIONS>
        </RULE>
    </DRUG>

    <DRUG>
        <NAME>TDF</NAME>
        <FULLNAME>tenofovir</FULLNAME>
        <RULE>
            <CONDITION>
                SCORE FROM (40F => 5,
                            41L => 5,
                            44DA => 5,
                            62V => 5,
                            MAX ( 65R => 60, 65N => 30 ),
                            MAX ( 66i => 45, 66d => 30 ),
                            MAX ( 67i => 45, 67d => 30, 67EGSTHN => 5 ),
                            MAX ( 68i => 45, 68d => 30 ),
                            MAX ( 69i => 45, 69d => 15, 69G => 5 ),
                            MAX ( 70i => 45, 70GEd => 15, 70RTSNQ => 10 ),
                            MAX ( 71i => 45, 71d => 15 ),
                            75I => 5,
                            77L => 5,
                            115F => 15,
                            116Y => 5,
                            118I => 5,
                            MAX ( 151M => 15, 151L => 10 ),
                            184VI AND EXCLUDE 184(NOT VI) => -10,
                            210W => 10,
                            MAX ( 215YF => 15, 215CDEIVSNAL => 10 ),
                            219QENRW => 5,
                            (118I AND 41L AND 215FY) => 5,
                            (210W AND 215FY) => 10,
                            (210W AND 215SCDEIVNAL) => 5,
                            (40F AND 41L AND 215FY) => 5,
                            (41L AND 210W) => 10,
                            (41L AND 215FY) => 10,
                            (41L AND 215SCDEIVNAL) => 5,
                            (44AD AND 41L AND 215FY) => 5,
                            (65N AND 184VI) => 10,
                            (65R AND 115F) => 15,
                            (65R AND 151M) => 15,
                            (65R AND 184VI) => 10,
                            (65R AND 62V) => 10,
                            (67NG AND 70R AND 219QENR) => 10,
                            (70EG AND 184VI) => 10
                           )
            </CONDITION>
            <ACTIONS>
                <SCORERANGE><USE_GLOBALRANGE/></SCORERANGE>
            </ACTIONS>
        </RULE>
    </DRUG>

    <DRUG>
        <NAME>FPV/r</NAME>
        <FULLNAME>fosamprenavir/r</FULLNAME>
        <RULE>
            <CONDITION>
                SCORE FROM (10F => 10,
                            11IL => 5,
                            24I => 5,
                            32I => 30,
                            33F => 10,
                            MAX ( 46IL => 10, 46V => 5 ),
                            MAX ( 47A => 60, 47V => 30 ),
                            MAX ( 50V => 60, 50L AND EXCLUDE 50(NOT L) => -5 ),
                            MAX ( 54LM => 60, 54ASTV => 10 ),
                            71IL => 5,
                            73ACST => 5,
                            MAX ( 74S => 5, 74P => 3 ),
                            76V => 60,
                            MAX ( 82F => 30, 82ACLMST => 10 ),
                            MAX ( 84AV => 60, 84C => 30 ),
                            88S AND EXCLUDE 88(NOT S) => -10,
                            89V => 5,
                            90M => 20,
                            (46ILV AND 82ATS) => 5,
                            (46ILV AND 82ATS AND 10IFVRY) => 5,
                            (46ILV AND 82ATS AND 71VTLI) => 5,
                            (54AVSTLM AND 82ATS) => 5,
                            (54AVSTLM AND 82ATS AND 10IFVRY) => 5,
                            (54AVSTLM AND 82ATS AND 71VTLI) => 5
                           )
            </CONDITION>
            <ACTIONS>
                <SCORERANGE><USE_GLOBALRANGE/></SCORERANGE>
            </ACTIONS>
        </RULE>

    </DRUG>

    <DRUG>
        <NAME>DRV/r</NAME>
        <FULLNAME>darunavir/r</FULLNAME>
        <RULE>
            <CONDITION>
                SCORE FROM (32I => 20,
                            33F => 5,
                            47AV => 10,
                            MAX ( 50V => 20, 50L AND EXCLUDE 50(NOT L) => -5 ),
                            54LM => 20,
                            76V => 20,
                            82F => 15,
                            84ACV => 10,
                            88S AND EXCLUDE 88(NOT S) => -5,
                            89V => 5,
                            (32I AND 47VA AND 54ML) => 10,
                            (32I AND 47VA AND 54ML AND 10F) => 5,
                            (32I AND 47VA AND 54ML AND 11IL) => 5,
                            (32I AND 47VA AND 54ML AND 33F) => 5,
                            (32I AND 47VA AND 54ML AND 73SCTA) => 5,
                            (32I AND 47VA AND 54ML AND 74P) => 5,
                            (32I AND 47VA AND 54ML AND 89V) => 5,
                            (32I AND 54ML AND 84VA) => 10,
                            (32I AND 54ML AND 84VA AND 10F) => 5,
                            (32I AND 54ML AND 84VA AND 11IL) => 5,
                            (32I AND 54ML AND 84VA AND 33F) => 5,
                            (32I AND 54ML AND 84VA AND 73SCTA) => 5,
                            (32I AND 54ML AND 84VA AND 74P) => 5,
                            (32I AND 54ML AND 84VA AND 89V) => 5
                           )
            </CONDITION>
            <ACTIONS>
                <SCORERANGE><USE_GLOBALRANGE/></SCORERANGE>
            </ACTIONS>
        </RULE>

	<RULE>
	    <CONDITION>SELECT ATLEAST 1 FROM (11I,32I,33F,47V,50V,54LM,74P,76V,84V,89V)
            </CONDITION>
	    <ACTIONS>
	        <COMMENT ref="PR_DRVr_Special" />
	    </ACTIONS>
	</RULE>

    </DRUG>

    <DRUG>
        <NAME>IDV/r</NAME>
        <FULLNAME>indinavir/r</FULLNAME>
        <RULE>
            <CONDITION>
                SCORE FROM (10F => 5,
                            24I => 10,
                            32I => 15,
                            MAX ( 46IL => 10, 46V => 5 ),
                            MAX ( 47A => 15, 47V => 10 ),
                            48ALMQSTV => 10,
                            50L AND EXCLUDE 50(NOT L) => -5,
                            MAX ( 54ASTV => 15, 54LM => 10 ),
                            73ACST => 5,
                            76V => 30,
                            MAX ( 82AFST => 30, 82M => 15, 82CL => 10 ),
                            83D => 5,
                            MAX ( 84A => 60, 84CV => 30 ),
                            88S => 10,
                            89V => 5,
                            90M => 20,
                            (32I AND 47VA) => 10,
                            (32I AND 47VA AND 54ML) => 10,
                            (32I AND 47VA AND 54ML AND 10F) => 10,
                            (32I AND 47VA AND 54ML AND 73SCTA) => 10,
                            (32I AND 47VA AND 54ML AND 89V) => 5,
                            (32I AND 47VA AND 54ML AND 90M) => 10,
                            (32I AND 54ML AND 84VA) => 10,
                            (32I AND 54ML AND 84VA AND 10F) => 10,
                            (32I AND 54ML AND 84VA AND 73SCTA) => 10,
                            (32I AND 54ML AND 84VA AND 89V) => 5,
                            (32I AND 54ML AND 84VA AND 90M) => 10,
                            (46IL AND 76V) => 10,
                            (46ILV AND 90M) => 10,
                            (54VSTA AND 82AFST AND 10F) => 10,
                            (54VSTA AND 82AFST AND 10IVR) => 5,
                            (54VSTA AND 82AFST AND 24I) => 10,
                            (54VSTA AND 82AFST AND 46ILV) => 10,
                            (54VSTA AND 82AFST AND 90M) => 10,
                            (73STCA AND 90M) => 10,
                            (90M AND 84V) => 10
                           )
            </CONDITION>
            <ACTIONS>
                <SCORERANGE><USE_GLOBALRANGE/></SCORERANGE>
            </ACTIONS>
        </RULE>
    </DRUG>

    <DRUG>
        <NAME>LPV/r</NAME>
        <FULLNAME>lopinavir/r</FULLNAME>
        <RULE>
            <CONDITION>
                SCORE FROM (10F => 5,
                            24I => 10,
                            32I => 15,
                            33F => 5,
                            MAX ( 46IL => 10, 46V => 5 ),
                            MAX ( 47A => 60, 47V => 15 ),
                            48ALMQSTV => 10,
                            MAX ( 50V => 20, 50L AND EXCLUDE 50(NOT L) => -5 ),
                            MAX ( 54LM => 15, 54ASTV => 10 ),
                            73ACST => 5,
                            76V => 30,
                            MAX ( 82AFST => 25, 82CLM => 10 ),
                            MAX ( 84A => 30, 84CV => 15 ),
                            90M => 10,
                            (32I AND 47VA) => 10,
                            (32I AND 47VA AND 54ML) => 10,
                            (32I AND 47VA AND 54ML AND 10F) => 10,
                            (32I AND 47VA AND 54ML AND 33F) => 10,
                            (32I AND 47VA AND 54ML AND 73SCTA) => 10,
                            (32I AND 47VA AND 54ML AND 89V) => 5,
                            (32I AND 47VA AND 54ML AND 90M) => 10,
                            (32I AND 54ML AND 84VA) => 10,
                            (32I AND 54ML AND 84VA AND 10F) => 10,
                            (32I AND 54ML AND 84VA AND 33F) => 10,
                            (32I AND 54ML AND 84VA AND 73SCTA) => 10,
                            (32I AND 54ML AND 84VA AND 89V) => 5,
                            (32I AND 54ML AND 84VA AND 90M) => 10,
                            (46IL AND 76V) => 10,
                            (54VSTA AND 82AFST AND 10F) => 10,
                            (54VSTA AND 82AFST AND 10IVR) => 5,
                            (54VSTA AND 82AFST AND 24I) => 10,
                            (54VSTA AND 82AFST AND 46ILV) => 10,
                            (54VSTA AND 82AFST AND 90M) => 10,
                            (90M AND 84V) => 5
                           )
            </CONDITION>
            <ACTIONS>
                <SCORERANGE><USE_GLOBALRANGE/></SCORERANGE>
            </ACTIONS>
        </RULE>
    </DRUG>

    <DRUG>
        <NAME>ATV/r</NAME>
        <FULLNAME>atazanavir/r</FULLNAME>
        <RULE>
            <CONDITION>
                SCORE FROM (24I => 5,
                            32I => 15,
                            33F => 5,
                            MAX ( 46IL => 10, 46V => 5 ),
                            47AV => 5,
                            MAX ( 48MV => 30, 48ALQST => 10 ),
                            50L => 60,
                            53L => 5,
                            54ALMSTV => 15,
                            58E => 5,
                            71IL => 5,
                            73ACST => 10,
                            74P => 5,
                            76V AND EXCLUDE 76(NOT V) => -5,
                            MAX ( 82AFST => 15, 82CLM => 10 ),
                            83D => 5,
                            MAX ( 84A => 60, 84V => 40, 84C => 30 ),
                            MAX ( 88S => 60, 88DGT => 10 ),
                            90M => 20,
                            (10IVFRY AND 90M) => 5,
                            (46ILV AND 82ATS) => 5,
                            (46ILV AND 82ATS AND 10IFVRY) => 5,
                            (46ILV AND 82ATS AND 71VTLI) => 5,
                            (53L AND 90M) => 5,
                            (54AVSTLM AND 82ATS) => 5,
                            (54AVSTLM AND 82ATS AND 10IFVRY) => 5,
                            (54AVSTLM AND 82ATS AND 71VTLI) => 5,
                            (71VTLI AND 90M) => 5,
                            (73STCA AND 90M) => 10
                           )
            </CONDITION>
            <ACTIONS>
                <SCORERANGE><USE_GLOBALRANGE/></SCORERANGE>
            </ACTIONS>
        </RULE>
    </DRUG>

    <DRUG>
        <NAME>TPV/r</NAME>
        <FULLNAME>tipranavir/r</FULLNAME>
        <RULE>
            <CONDITION>
                SCORE FROM (24I AND EXCLUDE 24(NOT I) => -5,
                            32I => 5,
                            33F => 5,
                            35G => 5,
                            43T => 10,
                            47AV => 20,
                            50LV AND EXCLUDE 50(NOT LV) => -5,
                            MAX ( 54AMSTV => 15, 54L AND EXCLUDE 54(NOT L) => -10 ),
                            58E => 10,
                            74P => 20,
                            76V AND EXCLUDE 76(NOT V) => -5,
                            MAX ( 82LT => 40, 82S => 15, 82CM => 10 ),
                            83D => 20,
                            MAX ( 84AV => 30, 84C => 15 )
                           )
            </CONDITION>
            <ACTIONS>
                <SCORERANGE><USE_GLOBALRANGE/></SCORERANGE>
            </ACTIONS>
        </RULE>

	<RULE>
	    <CONDITION>SELECT ATLEAST 1 FROM (47V,54AMV,58E,74P,82LT,83D,10V,36I,43T,46L,84V,24I,50LV,54L,76V)
            </CONDITION>
	    <ACTIONS>
	        <COMMENT ref="PR_TPVr_Special" />
	    </ACTIONS>
	</RULE>

    </DRUG>

    <DRUG>
        <NAME>NFV</NAME>
        <FULLNAME>nelfinavir</FULLNAME>
        <RULE>
            <CONDITION>
                SCORE FROM (MAX ( 10F => 10, 10IRVY => 5 ),
                            20IT => 10,
                            23I => 15,
                            24I => 5,
                            30N => 60,
                            32I => 15,
                            33F => 5,
                            35G => 5,
                            MAX ( 46IL => 15, 46V => 10 ),
                            MAX ( 47A => 30, 47V => 15 ),
                            MAX ( 48MV => 30, 48ALQST => 15 ),
                            MAX ( 50V => 10, 50L AND EXCLUDE 50(NOT L) => -5 ),
                            54ALMSTV => 15,
                            58E => 5,
                            71ILTV => 5,
                            73ACST => 10,
                            MAX ( 74S => 15, 74P => 10 ),
                            MAX ( 82AFST => 30, 82CLM => 10 ),
                            83D => 5,
                            84ACV => 60,
                            MAX ( 88S => 60, 88DGT => 30 ),
                            89V => 5,
                            90M => 60
                           )
            </CONDITION>
            <ACTIONS>
                <SCORERANGE><USE_GLOBALRANGE/></SCORERANGE>
            </ACTIONS>
        </RULE>
    </DRUG>

    <DRUG>
        <NAME>SQV/r</NAME>
        <FULLNAME>saquinavir/r</FULLNAME>
        <RULE>
            <CONDITION>
                SCORE FROM (24I => 5,
                            46V => 5,
                            MAX ( 48MV => 60, 48ALQST => 30 ),
                            MAX ( 50V => 5, 50L AND EXCLUDE 50(NOT L) => -5 ),
                            53L => 10,
                            MAX ( 54ASTV => 15, 54LM => 10 ),
                            71IL => 5,
                            73ACST => 10,
                            76V AND EXCLUDE 76(NOT V) => -5,
                            82ACLMST => 10,
                            83D => 5,
                            84ACV => 60,
                            88DS => 5,
                            90M => 40,
                            (10IVFRY AND 90M) => 5,
                            (46ILV AND 82ATS) => 5,
                            (46ILV AND 82ATS AND 10IFVRY) => 5,
                            (46ILV AND 82ATS AND 71VTLI) => 5,
                            (53L AND 90M) => 5,
                            (54AVSTLM AND 82ATS) => 5,
                            (54AVSTLM AND 82ATS AND 10IFVRY) => 5,
                            (54AVSTLM AND 82ATS AND 71VTLI) => 5,
                            (71VTLI AND 90M) => 5,
                            (73STCA AND 90M) => 10
                           )
            </CONDITION>
            <ACTIONS>
                <SCORERANGE><USE_GLOBALRANGE/></SCORERANGE>
            </ACTIONS>
        </RULE>
    </DRUG>

    <DRUG>
        <NAME>RAL</NAME>
        <FULLNAME>raltegravir</FULLNAME>
        <RULE>
            <CONDITION>
                SCORE FROM (51Y => 15,
                            MAX ( 66K => 60, 66A => 15, 66I => 10 ),
                            74M => 10,
                            MAX ( 92QV => 30, 92G => 15 ),
                            95K => 5,
                            97A => 10,
                            121Y => 30,
                            138AK => 15,
                            140ACS => 30,
                            MAX ( 143CR => 60, 143HK => 45 ),
                            148HKR => 60,
                            MAX ( 151L => 30, 151A => 15, 151I => 5 ),
                            MAX ( 155H => 60, 155ST => 30 ),
                            157Q => 10,
                            163KR => 10,
                            230R => 10,
                            263K => 10
                           )
            </CONDITION>
            <ACTIONS>
                <SCORERANGE><USE_GLOBALRANGE/></SCORERANGE>
            </ACTIONS>
        </RULE>
    </DRUG>

    <DRUG>
        <NAME>EVG</NAME>
        <FULLNAME>elvitegravir</FULLNAME>
        <RULE>
            <CONDITION>
                SCORE FROM (51Y => 15,
                            66AIK => 60,
                            74M => 10,
                            MAX ( 92QV => 60, 92G => 30 ),
                            95K => 5,
                            97A => 10,
                            114Y => 5,
                            121Y => 30,
                            128T => 5,
                            138AK => 15,
                            140ACS => 30,
                            145S => 60,
                            146P => 30,
                            147G => 60,
                            148HKR => 60,
                            MAX ( 151L => 60, 151A => 30, 151I => 5 ),
                            MAX ( 153Y => 15, 153F => 10 ),
                            MAX ( 155H => 60, 155ST => 30 ),
                            157Q => 10,
                            163KR => 10,
                            230R => 10,
                            263K => 20
                           )
            </CONDITION>
            <ACTIONS>
                <SCORERANGE><USE_GLOBALRANGE/></SCORERANGE>
            </ACTIONS>
        </RULE>
    </DRUG>

    <DRUG>
        <NAME>DTG</NAME>
        <FULLNAME>dolutegravir</FULLNAME>
        <RULE>
            <CONDITION>
                SCORE FROM (51Y => 10,
                            66K => 10,
                            74M => 5,
                            MAX ( 92GQ => 10, 92V => 5 ),
                            97A => 5,
                            121Y => 5,
                            138AK => 10,
                            140ACS => 10,
                            MAX ( 148K => 30, 148HR => 20 ),
                            151L => 15,
                            153FY => 10,
                            155H => 10,
                            263K => 10,
                            (148HRK AND 138AK) => 20,
                            (148HRK AND 140SAC) => 20,
                            (148HRK AND 163RK) => 5,
                            (148HRK AND 74M) => 5,
                            (148HRK AND 97A) => 5
                           )
            </CONDITION>
            <ACTIONS>
                <SCORERANGE><USE_GLOBALRANGE/></SCORERANGE>
            </ACTIONS>
        </RULE>
    </DRUG>

    <MUTATION_COMMENTS>
        <GENE>
            <NAME>PR</NAME>
<!-- Begin the PR rules for mutation-dependent comment strings. -->
            <RULE>
                <CONDITION>10(NOT LIVFRY)</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS10ACDEGHKMNPQSTWdi_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>10IVFRY</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS10IVFRY_PIMinor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>11IL</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS11IL_PIMinor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>20(NOT KRIMTV)</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS20ACDEFGHLNPQSWYdi_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>20RMITV</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS20RMITV_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>23(NOT LI)</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS23ACDEFGHKMNPQRSTVWYdi_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>23I</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS23I_PIMinor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>24(NOT LFI)</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS24ACDEGHKMNPQRSTVWYdi_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>24F</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS24F_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>24I</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS24I_PIMinor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>30(NOT DN)</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS30ACEFGHIKLMPQRSTVWYdi_PIMinor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>30N</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS30N_PIMajor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>32(NOT VI)</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS32ACDEFGHKLMNPQRSTWYdi_PIMinor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>32I</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS32I_PIMajor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>33F</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS33F_PIMinor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>33I</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS33I_PIMinor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>33V</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS33V_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>35G</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS35G_PIMinor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>36ILTV</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS36ILTV_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>43T</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS43T_PIMinor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>46(NOT MILV)</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS46ACDEFGHKNPQRSTWYdi_PIMinor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>46IL</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS46IL_PIMajor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>46V</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS46V_PIMinor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>47A</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS47A_PIMajor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>47(NOT IAV)</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS47CDEFGHKLMNPQRSTWYdi_PIMinor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>47V</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS47V_PIMajor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>48ASTQL</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS48ASTQL_PIMajor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>48(NOT GVMALSTQ)</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS48CDEFHIKNPRWYdi_PIMinor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>48M</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS48M_PIMajor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>48V</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS48V_PIMajor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>50(NOT ILV)</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS50ACDEFGHKMNPQRSTWYdi_PIMinor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>50L</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS50L_PIMajor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>50V</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS50V_PIMajor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>53(NOT FLY)</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS53ACDEGHIKMNPQRSTVWdi_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>53LY</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS53LY_PIMinor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>54(NOT IALMSTV)</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS54CDEFGHKNPQRWYdi_PIMinor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>54L</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS54L_PIMajor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>54M</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS54M_PIMajor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>54TAS</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS54TAS_PIMajor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>54V</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS54V_PIMajor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>58E</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS58E_PIMinor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>63P</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS63P_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>71TVIL</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS71TVIL_PIMinor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>73STCA</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS73STCA_PIMinor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>74P</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS74P_PIMinor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>74S</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS74S_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>76(NOT LV)</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS76ACDEFGHIKMNPQRSTWYdi_PIMinor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>76V</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS76V_PIMajor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>77I</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS77I_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>82A</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS82A_PIMajor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>82C</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS82C_PIMajor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>82(NOT VATIFLMSC)</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS82DEGHKNPQRWYdi_PIMinor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>82F</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS82F_PIMajor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>82I</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS82I_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>82L</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS82L_PIMajor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>82M</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS82M_PIMajor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>82S</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS82S_PIMajor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>82T</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS82T_PIMajor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>83(NOT ND)</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS83ACEFGHIKLMPQRSTVWYdi_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>83D</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS83D_PIMinor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>84AC</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS84AC_PIMajor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>84(NOT IACV)</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS84DEFGHKLMNPQRSTWYdi_PIMinor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>84V</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS84V_PIMajor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>85V</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS85V_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>88(NOT NDGST)</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS88ACEFHIKLMPQRVWYdi_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>88D</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS88D_PIMinor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>88S</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS88S_PIMajor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>88TG</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS88TG_PIMajor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>89IT</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS89IT_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>89M</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS89M_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>89V</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS89V_PIMinor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>90(NOT LM)</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS90ACDEFGHIKNPQRSTVWYdi_PIMinor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>90M</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS90M_PIMajor" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>93L</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS93L_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>93M</CONDITION>
                <ACTIONS><COMMENT ref="PR_POS93M_Other" /></ACTIONS>
            </RULE>
<!-- End the PR rules for mutation-dependent comment strings. -->
        </GENE>
        <GENE>
            <NAME>RT</NAME>
<!-- Begin the RT rules for mutation-dependent comment strings. -->
            <RULE>
                <CONDITION>40F</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS40F_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>41(NOT MIL)</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS41ACDEFGHKNPQRSTVWYdi_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>41I</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS41I_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>41L</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS41L_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>44AD</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS44AD_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>62(NOT AV)</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS62CDEFGHIKLMNPQRSTWYdi_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>62V</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS62V_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>65(NOT KNR)</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS65ACDEFGHILMPQSTVWYdi_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>65N</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS65N_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>65R</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS65R_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>66d</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS66d_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>66i</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS66i_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>67(NOT DEGNSTHd)</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS67ACFIKLMPQRVWYi_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>67EGSTQH</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS67EGSTQH_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>67N</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS67N_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>67d</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS67d_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>67i</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS67i_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>68d</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS68d_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>68i</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS68i_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>69(NOT TADGIENSi)</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS69CFHKLMPQRVWYd_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>69D</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS69D_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>69G</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS69G_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>69N</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS69N_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>69SAIE</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS69SAIE_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>69d</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS69d_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>69i</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS69i_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>70(NOT KEGNQRST)</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS70ACDFHILMPVWYdi_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>70EG</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS70EG_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>70QNST</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS70QNST_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>70R</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS70R_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>70d</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS70d_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>70i</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS70i_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>71d</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS71d_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>71i</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS71i_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>74(NOT LIV)</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS74ACDEFGHKMNPQRSTWYdi_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>74IV</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS74IV_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>75(NOT VAIMSTL)</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS75CDEFGHKNPQRWYdi_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>75I</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS75I_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>75M</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS75M_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>75SAL</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS75SAL_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>75T</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS75T_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>77(NOT FL)</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS77ACDEGHIKMNPQRSTVWYdi_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>77L</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS77L_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>90I</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS90I_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>98G</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS98G_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>100(NOT LI)</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS100ACDEFGHKMNPQRSTVWYdi_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>100I</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS100I_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>100V</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS100V_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>101(NOT KEHNPQR)</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS101ACDFGILMSTVWYdi_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>101E</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS101E_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>101H</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS101H_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>101N</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS101N_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>101P</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS101P_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>101Q</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS101Q_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>101R</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS101R_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>103(NOT KEHNQRST)</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS103ACDFGILMPVWYdi_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>103EQ</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS103EQ_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>103H</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS103H_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>103N</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS103N_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>103R</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS103R_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>103S</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS103S_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>103T</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS103T_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>106A</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS106A_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>106(NOT VAIM)</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS106CDEFGHKLNPQRSTWYdi_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>106I</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS106I_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>106M</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS106M_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>108(NOT VI)</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS108ACDEFGHKLMNPQRSTWYdi_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>108I</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS108I_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>115(NOT YF)</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS115ACDEGHIKLMNPQRSTVWdi_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>115F</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS115F_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>116(NOT FY)</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS116ACDEGHIKLMNPQRSTVWdi_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>116Y</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS116Y_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>118I</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS118I_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>132ML</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS132ML_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>138A</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS138A_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>138(NOT EAGKQR)</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS138CDFHILMNPSTVWYdi_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>138GQR</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS138GQR_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>138K</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS138K_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>151(NOT QLM)</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS151ACDEFGHIKNPRSTVWYdi_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>151L</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS151L_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>151M</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS151M_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>179(NOT VDEFILT)</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS179ACGHKMNPQRSWYdi_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>179DE</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS179DE_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>179F</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS179F_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>179I</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS179I_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>179L</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS179L_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>179T</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS179T_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>181(NOT YCIVSFG)</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS181ADEHKLMNPQRTWdi_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>181C</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS181C_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>181FSG</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS181FSG_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>181IV</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS181IV_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>184(NOT MIV)</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS184ACDEFGHKLNPQRSTWYdi_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>184VI</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS184VI_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>188(NOT YCFHL)</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS188ADEGIKMNPQRSTVWdi_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>188C</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS188C_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>188F</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS188F_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>188H</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS188H_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>188L</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS188L_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>190A</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS190A_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>190CTV</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS190CTV_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>190(NOT GACEQSTV)</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS190DFHIKLMNPRWYdi_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>190EQ</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS190EQ_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>190S</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS190S_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>210(NOT LWSF)</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS210ACDEGHIKMNPQRTVYdi_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>210W</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS210W_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>210W</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS210W_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>215F</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS215F_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>215(NOT TCDEFISVYALN)</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS215GHKMPQRWdi_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>215SCDEIVALN</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS215SCDEIVALN_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>215Y</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS215Y_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>219(NOT KENQRW)</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS219ACDFGHILMPSTVYdi_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>219NR</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS219NR_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>219QE</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS219QE_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>219W</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS219W_NRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>221(NOT HY)</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS221ACDEFGIKLMNPQRSTVWdi_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>221Y</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS221Y_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>225(NOT PH)</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS225ACDEFGIKLMNQRSTVWYdi_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>225H</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS225H_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>227(NOT FCL)</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS227ADEGHIKMNPQRSTVWYdi_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>227C</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS227C_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>227L</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS227L_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>230(NOT ML)</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS230ACDEFGHIKNPQRSTVWYdi_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>230L</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS230L_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>236(NOT PL)</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS236ACDEFGHIKMNQRSTVWYdi_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>236L</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS236L_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>238(NOT KNRT)</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS238ACDEFGHILMPQSVWYdi_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>238R</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS238R_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>238TN</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS238TN_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>318(NOT YF)</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS318ACDEGHIKLMNPQRSTVWdi_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>318F</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS318F_NNRTI" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>348(NOT NI)</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS348ACDEFGHKLMPQRSTVWYdi_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>348I</CONDITION>
                <ACTIONS><COMMENT ref="RT_POS348I_NNRTI" /></ACTIONS>
            </RULE>
<!-- End the RT rules for mutation-dependent comment strings. -->
        </GENE>
        <GENE>
            <NAME>IN</NAME>
<!-- Begin the IN rules for mutation-dependent comment strings. -->
            <RULE>
                <CONDITION>51(NOT HY)</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS51ACDEFGIKLMNPQRSTVWdi_Accessory" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>51Y</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS51Y_Accessory" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>66A</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS66A_Major" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>66(NOT TIAK)</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS66CDEFGHLMNPQRSVWYdi_Major" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>66I</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS66I_Major" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>66K</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS66K_Major" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>68VI</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS68VI_Accessory" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>74M</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS74M_Accessory" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>92(NOT EQVG)</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS92ACDFHIKLMNPRSTWYdi_Major" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>92G</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS92G_Major" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>92Q</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS92Q_Major" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>92V</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS92V_Major" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>95(NOT QK)</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS95ACDEFGHILMNPRSTVWYdi_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>95K</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS95K_Accessory" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>97A</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS97A_Accessory" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>97(NOT TA)</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS97CDEFGHIKLMNPQRSVWYdi_Accessory" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>114(NOT HY)</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS114ACDEFGIKLMNPQRSTVWdi_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>114Y</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS114Y_Accessory" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>118(NOT GR)</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS118ACDEFHIKLMNPQSTVWYdi_Accessory" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>118R</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS118R_Major" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>121(NOT FY)</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS121ACDEGHIKLMNPQRSTVWdi_Accessory" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>121Y</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS121Y_Major" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>128(NOT AT)</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS128CDEFGHIKLMNPQRSVWYdi_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>128T</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS128T_Accessory" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>138(NOT EKA)</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS138CDFGHILMNPQRSTVWYdi_Accessory" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>138KA</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS138KA_Accessory" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>140(NOT GSAC)</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS140DEFHIKLMNPQRTVWYdi_Accessory" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>140SAC</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS140SAC_Accessory" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>143(NOT YCRHK)</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS143ADEFGILMNPQSTVWdi_Major" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>143CRHK</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS143CRHK_Major" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>145(NOT PS)</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS145ACDEFGHIKLMNQRTVWYdi_Major" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>145S</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS145S_Major" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>146(NOT QP)</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS146ACDEFGHIKLMNRSTVWYdi_Major" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>146P</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS146P_Major" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>147(NOT SG)</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS147ACDEFHIKLMNPQRTVWYdi_Major" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>147G</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS147G_Major" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>148(NOT QHKR)</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS148ACDEFGILMNPSTVWYdi_Major" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>148HKR</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS148HKR_Major" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>151A</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS151A_Accessory" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>151(NOT VIAL)</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS151CDEFGHKMNPQRSTWYdi_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>151I</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS151I_Accessory" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>151L</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS151L_Major" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>153(NOT SYF)</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS153ACDEGHIKLMNPQRTVWdi_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>153YF</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS153YF_Accessory" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>155(NOT NHST)</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS155ACDEFGIKLMPQRVWYdi_Major" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>155H</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS155H_Major" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>155ST</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS155ST_Major" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>157(NOT EQ)</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS157ACDFGHIKLMNPRSTVWYdi_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>157Q</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS157Q_Accessory" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>163RK</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS163RK_Accessory" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>230R</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS230R_Accessory" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>263(NOT RK)</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS263ACDEFGHILMNPQSTVWYdi_Other" /></ACTIONS>
            </RULE>

            <RULE>
                <CONDITION>263K</CONDITION>
                <ACTIONS><COMMENT ref="IN_POS263K_Accessory" /></ACTIONS>
            </RULE>
<!-- End the IN rules for mutation-dependent comment strings. -->
        </GENE>
    </MUTATION_COMMENTS>
</ALGORITHM>
